Direct-to-Patient Market Report 2021-2031: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.
Direct-to-Patient Healthcare Model is Gaining Tractions Globally
Direct-to-Patient programmes are being considered not just as a cost-effective alternative to the traditional paradigm, but also as an incentive to improve patient enrolment, shorten trial periods, and reduce total costs. Direct-to-Patient programmes will be a very useful tool for a more robust clinical trial provided the solution is deemed a good fit for the study and proper due diligence is carried out.
In the future years, technological advancements, particularly enhanced measuring technologies, will continue to improve the approach, enhancing the patient experience and providing stakeholders with a clearer perspective of the supply chain. With this in mind, advertisers should start looking into whether or not this strategy is viable for future trials.
The Integration of DTP with the hospitals, clinics and medical university opens up a wider range of opportunities
The integration of the DTP into hospitals, clinics and medical universities offers companies a broader range of opportunities to receive on-site further training in clinical trials. Many seminars are offered free of charge to employees, such as medicines training, drug equipment, good clinical practice, design of studies, pharmacovigilance, and clinical trial analysis and interpretation.
You need to discover how this will impact the direct-to-patient market today, and over the next 10 years:
• Our 691-page report provides 402 tables and 356 charts/graphs exclusively to you.
• The report highlights key lucrative areas in the industry so you can target them – NOW.
• Contains in-depth analysis of global, regional and national sales and growth
• Highlights for you the key successful trends, changes and revenue projections made by your competitors
This report tells you TODAY how the direct-to-patient market will develop in the next 10 years, and in line with the variations in COVID-19 economic recession and bounce. This market is more critical now than at any point over the last 10 years.
This report includes data analysis and invaluable insight into how COVID-19 will affect your industry. Access this report today.
To access the data contained in this document please email contactus@visiongain.com
Forecasts to 2031 and other analyses reveal the commercial prospects
• In addition to revenue forecasting to 2031, our new study provides you with recent results, growth rates, and market shares.
• You find original analyses, with business outlooks and developments.
• Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), cost structure, the impact of rising direct-to-patient prices and recent developments.
This report includes data analysis and invaluable insight into how COVID-19 will affect the industry and your company. Four COVID-19 recovery patterns and their impact, namely, V, L, W and U are discussed in this report.
Global Direct-to-Patient Market Breakdown by Type (COVID Impact Analysis)
• Direct-to-Patient Marketing
• Direct-to-Patient Health Services
• Direct-to-Patient Clinical Trials
• Direct-to-Patient Logistics
Global Direct-to-Patient Market Breakdown by Direct-to-Patient Marketing (COVID Impact Analysis)
• DTC Prescribed Drug Advertising
• Disease Awareness Campaigns
• Brand Promotion
• Healthcare Services Promotion
• Laboratory Testing Promotion
• Other Direct-to-Patient Marketing
Global Direct-to-Patient Market Breakdown by Direct-to-Patient Health Services (COVID Impact Analysis)
• Tele Consultation
• Drug Prescription
• Medical Call Centers
• Telesampling
• Online Services
Global Direct-to-Patient Market Breakdown by Clinical Trials (COVID Impact Analysis)
• Tele Health Screening
• Investigational Medicinal Product (IMP)
• Patient Support Systems
• Other Clinical Trial Services
Global Direct-to-Patient Market Breakdown by Logistics (COVID Impact Analysis)
• Prescribed Medicine Delivery
• Pre-Clinical Supplies
• Clinical Trial Supplies
• Home Trial Support
• Test Samples Collection
• Rest All CSO Services
Global Direct-to-Patient Market Breakdown by Therapeutics (COVID Impact Analysis)
• Cardiovascular Disease
• Respiratory Diseases
• Oncology
• Infectious Diseases
• Dermatology
• Other Therapeutics
Global Direct-to-Patient Market Breakdown by Model (COVID Impact Analysis)
• Investigator Site Pharmacy
• Central Pharmacy
• Depot Distribution to Local Pharmacy
• Direct from Patient
• Other DtP Models
In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for 4 regional and 20 leading national markets:
• North America Direct-to-Patient Market, 2021 to 2031 Market Outlook
• U.S. Direct-to-Patient Market, 2021 to 2031 Market Forecast & COVID Impact Analysis
• Canada Direct-to-Patient Market, 2021 to 2031 Market Forecast & COVID Impact Analysis
• Mexico Direct-to-Patient Market, 2021 to 2031 Market Forecast & COVID Impact Analysis
• Europe Direct-to-Patient Market, 2021 to 2031 Market Outlook
• Germany Direct-to-Patient Market, 2021 to 2031 Market Forecast & COVID Impact Analysis
• Spain Direct-to-Patient Market, 2021 to 2031 Market Forecast & COVID Impact Analysis
• United Kingdom Direct-to-Patient Market, 2021 to 2031 Market Forecast & COVID Impact Analysis
• France Direct-to-Patient Market, 2021 to 2031 Market Forecast & COVID Impact Analysis
• Italy Direct-to-Patient Market, 2021 to 2031 Market Forecast & COVID Impact Analysis
• Rest of Europe Direct-to-Patient Market, 2021 to 2031 Market Forecast & COVID Impact Analysis
• Asia Pacific Direct-to-Patient Market, 2021 to 2031 Market Outlook
• China Direct-to-Patient Market, 2021 to 2031 Market Forecast & COVID Impact Analysis
• Japan Direct-to-Patient Market, 2021 to 2031 Market Forecast & COVID Impact Analysis
• India Direct-to-Patient Market, 2021 to 2031 Market Forecast & COVID Impact Analysis
• Australia Direct-to-Patient Market, 2021 to 2031 Market Forecast & COVID Impact Analysis
• South Korea Direct-to-Patient Market, 2021 to 2031 Market Forecast & COVID Impact Analysis
• Rest of Asia Pacific Direct-to-Patient Market, 2021 to 2031 Market Forecast & COVID Impact Analysis
• LAMEA Direct-to-Patient Market, 2021 to 2031 Market Outlook
• Brazil Direct-to-Patient Market, 2021 to 2031 Market Forecast & COVID Impact Analysis
• Turkey Direct-to-Patient Market, 2021 to 2031 Market Forecast & COVID Impact Analysis
• Saudi Arabia Direct-to-Patient Market, 2021 to 2031 Market Forecast & COVID Impact Analysis
• South Africa Direct-to-Patient Market, 2021 to 2031 Market Forecast & COVID Impact Analysis
• UAE Direct-to-Patient Market, 2021 to 2031 Market Forecast & COVID Impact Analysis
• Rest of Latin America, Middle East and Africa Direct-to-Patient Market, 2021 to 2031 Market Forecast & COVID Impact Analysis
Need industry data? Please contact us today.
The report also includes profiles and for some of the leading companies in the Direct-to-Patient Market, 2021 to 2031, with a focus on this segment of these companies’ operations.
Leading companies and the potential for market growth:
• American Well Corporation
• Teladoc Health, Inc.
• Doctor on Demand
• Nurx
• Specialists On Call Inc.
• Babylon Health
• Dictum Health
• Doctor Anywhere Pte. Ltd.
• Practo Technologies Private Limited
• CitiusTech Inc.
• Hims & Hers Health, Inc.
• Health Tap
• Marken
• HealthPartners, Inc.
• Access Physicians
• 20/20NOW
• AGNITY Global Inc.
• AMD Global Telemedicine, Inc.
• Avera eCARE
• Axs Healthcare
• TRUEPILL, LTD
• UpScript Health
Overall world revenue for Direct-to-Patient Market, 2021 to 2031 in terms of value the market will surpass US$xx million in 2021, our work calculates. We predict strong revenue growth through 2031. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.
How the Direct-to-Patient Market, 2021 to 2031 Market report helps you?
In summary, our 690+ page report provides you with the following knowledge:
• Revenue forecasts to 2031 for Direct-to-Patient Market, 2021 to 2031 Market, with forecasts for market value, DtP Type, Direct-to-Patient Marketing, Direct-to-Patient Health Services, Direct-to-Patient Clinical Trials, Direct-to-Patient logistics, Therapeutics, Model each forecasted at a global and regional level– discover the industry’s prospects, finding the most lucrative places for investments and revenues
• Revenue forecasts to 2031 for 4 regional and 20 key national markets – See forecasts for the Direct-to-Patient Market, 2021 to 2031 market in North America, Europe, Asia-Pacific and LAMEA. Also forecasted are the market in the US, Canada, Mexico, Brazil, Germany, France, UK, Italy, China, India, Japan, and Australia among other prominent economies.
• Prospects for established firms and those seeking to enter the market– including company profiles for 20 of the major companies involved in the Direct-to-Patient Market, 2021 to 2031 Market.
Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with this invaluable business intelligence.
Information found nowhere else
With our newly report title, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Visiongain’s study is for everybody needing commercial analyses for the Direct-to-Patient Market, 2021 to 2031 Market and leading companies. You will find data, trends and predictions.
To access the data contained in this document please email contactus@visiongain.com
Buy our report today Direct-to-Patient Market Report 2021-2031: Forecasts by Type (Direct-to-Patient Marketing, Direct-to-Patient Health Services, Direct-to-Patient Clinical Trials, Direct-to-Patient Logistics), by Marketing (DTC Prescribed Drug Advertising, Disease Awareness Campaigns, Brand Promotion, Healthcare Services Promotion, Laboratory Testing Promotion, Other), by Health Services (Tele Consultation, Drug Prescription, Medical Call Centres, Tele-sampling, Online Services), by Clinical Trials (Tele Health Screening, Investigational Medicinal Product (IMP), Patient Support Systems, Other), by Market Logistics (Prescribed Medicine Delivery, Pre-Clinical Supplies, Clinical Trial Supplies, Home Trial Support, Test Samples Collection, Rest All CSO Services), by Therapeutic (Cardiovascular Disease, Respiratory Diseases, Oncology, Infectious Diseases, Dermatology, Other), by Model (Investigator Site Pharmacy, Central Pharmacy, Depot Distribution to Local Pharmacy, Direct from Patient, Other) AND Regional and Leading National Market Analysis PLUS Analysis of Leading DtP Companies AND COVID-19 Recovery Scenarios. Avoid missing out by staying informed – order our report now.
Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6
Do you have any custom requirements we can help you with? Any need for a specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help: sara.peerun@visiongain.com
1. Report Overview
1.1 Introduction to Direct-to-Patient Market
1.2 Global Direct-to-Patient Market Overview
1.3 What are the Objectives of this Report?
1.4 What is the Scope of the Report?
1.5 Direct-to-Patient Market Definition
1.6 Why You Should Read This Report
1.7 What This Report Delivers
1.8 Key Questions Answered By This Analytical Report Include:
1.9 Who is This Report for?
1.10 Research Methodology
1.10.1 Primary Research
1.10.2 Secondary Research
1.10.3 Market Evaluation & Forecasting Methodology
1.11 Frequently Asked Questions (FAQs)
1.12 Associated Visiongain Reports
1.13 About Visiongain
2 Executive Summary
2.1 Focus on More Patient-Centered Trial Designs
2.2 Finding and Retaining Patients
2.3 Increased Costs and Complexity of Traditional Research
3 Direct-to-Patient Industry Structure
3.1 Overview
3.1.1 Well-Designed E-Commerce Platforms and Appealing User Interfaces Results In Increased Customer Base
3.1.2 Firms Are Drawn to The Direct-To-Patient Method Because It Provides A Vast Client Base And Minimal Regulatory Obstacles To Entry
3.1.3 Direct-To-Patient Model Avoid the Traditional Filters And Protections Of Health-Care Systems
3.2 Direct-to-Patient Capabilities
3.2.1 India Is On The Verge Of ‘Leapfrogging' The Current Healthcare Ecosystem's Hurdles
3.2.2 A New Class Of Middlemen Will Arise To Construct The Digital Infrastructure's Core Base
3.3 Even Before The COVID-19 Pandemic, Decentralized Clinical Trials Have Increased
3.3.1 Advantages of DTP for Clinical Trials
4 Global Market Dynamics
4.1 Current Trends in the Global Market
4.1.1 The Pandemic Has Disrupted The Clinical Trial Supply Chain
4.1.2 The Respiratory Segment is Expected to Hold a Major Market Share
4.1.3 In-Home Drug Storage Direct-to-Patient Logistics
4.2 Market Driving Factors
4.2.1 DTP Model Can Help In Reducing Variability Between Sites
4.2.2 Clinical Trials And Drug Development Become More Competitive These Days
4.2.3 Clinical Trials in Progress Were in Trouble Due to Pandemic Outbreak
4.2.4 Pandemic has Compelled sponsors and CROs re-examining their protocols
4.2.5 How Technological Advances Are Driving the Market
4.2.6 Recognizing the Value of Direct-to-Patient
4.2.7 Trials Will Require Significantly Fewer Patients To Enrol In Clinical Trials Which Will Expedite Timelines
4.2.8 Startups Are Leading The Charge In Providing Data-Driven Supply Chain Management Solutions
4.3 Market Restraining Factors
4.3.1 Patient’s Travel Time And Money To Reach At The Clinical Site Are Been Ignored
4.3.2 Stringent Legal Regulations Hindering DTP Market Growth
4.3.3 Digital Technology Advancement Will Help to Increase Customer Base
4.3.4 Telehealth Consent is Booming
4.4 Opportunities in the Market
4.4.1 Appetite For Pharma Tech Services Is On The Rise, Creating A Surge Of Emerging Companies
4.4.2 COVID-19 Macroenvironment Has Highlighted Procedural Inefficiencies And Technological Disparities In Trial Administration
4.4.3 DTP Services are not limited to Medicinal Deliveries
4.4.4 DTP Would Be The First Point Of Contact To Support Patients In Near Future
4.4.5 The Integration Of The DTP Into The Hospitals, Clinics And Medical University Opens Up A Wider Range Of Opportunities
4.5 Challenges in the Global Market
4.5.1 Navigating The Varying And Rapidly Evolving Complex And Stringent Regulations In Each Country Is Challenging
4.5.2 Stiff Competition for Patients
4.5.3 Patient Requirement and Patient Retention is a Big Challenge
4.5.4 Distributors Trust
4.5.5 Finding and Retaining Patients
4.5.6 Regulatory Issues
4.5.7 Patient Confidentiality
4.6 SWOT Analysis for DTP Global Market
4.6.1 Strenghts of DTP Market
4.6.2 Weaknesses of DTP Market
4.6.3 Opportunities in DTP Market
4.6.4 Threats in DTP Market
4.7 PEST Analysis for Direct-to-Patient Global Market
4.7.1 Political Factors
4.7.2 Economic Factors
4.7.3 Social Factors
4.7.4 Technological Factors
4.8 Porter’s 5 Forces Model for Direct-to-Patient Global Market
4.9 Porter’s Five Forces Analysis:
4.9.1 Threat of New Entrants-High
4.9.2 Bargaining Power of Suppliers-Low
4.9.3 Bargainining Power of Buyers-Moderate
4.9.4 Threat of of Substitutes-High
4.9.5 Competitive Rivalry (Moderate)
5 Global Direct-to-Patient Market Analysis
5.1 Global Market Outlook
5.1.1 The COVID-19 Outbreak Has Greatly Impacted The Clinical Trial Ancillary Supply Value Chain From Pre-Clinical Through Data Analysis
5.1.2 Prior to the pandemic, DTP model had mostly been applied to small studies in the United States and Europe
5.1.3 Regional Reforms in Global Clinical Trials Industry
5.2 Global Market Size Estimation and Forecast
5.2.1 Pre-COVID-19 Market Scenario
5.2.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
6 Regional Market Size Estimation and Forecast
6.1 North America
6.2 Europe
6.3 Asia Pacific
6.4 LAMEA
6.5 Global Market Size Estimation and Forecast Analysis
6.5.1 Pre-COVID-19 Market Scenario
6.5.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
7 Global Market Size Estimation and Forecast by Type
7.1 Direct-to-Patient Marketing
7.2 Direct-to-Patient Health Services
7.3 Direct-to-Patient Clinical Trials
7.4 Direct-to-Patient Logistics
7.5 Global Market Size Estimation and Forecast Analysis by Type
7.5.1 Pre-COVID-19 Market Scenario
7.5.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
8 Global Market Size Estimation and Forecast by Marketing
8.1.1 Pre-COVID-19 Market Scenario
8.1.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
9 Global Market Size Estimation and Forecast by Health Services
9.1 Tele Consultation
9.2 Drug Prescription
9.3 Medical Call Centers
9.4 Telesampling
9.5 Online Services
9.5.1 Pre-COVID-19 Market Scenario
9.5.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
10 Global Market Size Estimation and Forecast by Clinical Trials
10.1 Tele Health Screening
10.2 Investigational Medicinal Product (IMP)
10.3 Patient Support Systems
10.3.1 Pre-COVID-19 Market Scenario
10.3.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
11 Global Market Size Estimation and Forecast by Logistics
11.1 Prescribed Medicine Delivery:
11.2 Pre-Clinical Supplies
11.3 Clinical Trial Supplies
11.4 Home Trial Support:
11.5 Test Samples Collection
11.5.1 Pre-COVID-19 Market Scenario
11.5.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
12 Global Market Size Estimation and Forecast by Therapeutic
12.1.1 Pre-COVID-19 Market Scenario
12.1.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
13 Global Market Size Estimation and Forecast by Model
13.1 Direct-to-Patient Model for Clinical Trials
13.2 Site-to-Patient
13.3 Depot-to-Patient
13.4 Hybrid Model
13.5 Direct from Patient
13.6 Other Direct-to-Patient Model
13.7 New DTP Models to Gain Tractions in Future
13.7.1 Patient-Centric Ecosystem /Patient Service Center (PSC)
13.7.2 There Has Never Been A Better Time To Be Building Digital Health Solutions For Clinical Trials
13.7.3 The Rise of the Direct-to- Patient Distribution Model
13.7.4 DTP Clinical Trial Model Is Projected To Grow Significantly Over The Next Few Years
13.7.5 A Well-Planned DTP Study Can Be Beneficial To Patients And Sponsors
13.7.6 DTP Model Is Ideal For Faster Recruitment And Higher Retention Rates
13.7.7 Marken Has Developed Its Global Home-Based Nursing Network To Supplement Its Existing Services
13.7.8 For Patients And Their Families/Caregivers, Treatment In The Home Is Much More Convenient Than Having To Travel To The Trial Site
13.7.9 The Direct-To-Patient Service Is Designed To Support Trials And Help To Minimize Trial Length And Costs, While Boosting Enrollment And Participation Rates.
13.7.10 The DtP paradigm is a game changer in Improving Recruitment & Retention
13.8 Digital Platforms and Technologies Are Critical for DTP Model Implementation
13.8.1 How Digital DTP Platform Helps Smooth Functioning Of Siteless/Hybrid Trials?
13.8.2 DTP Model Provided End-to-End Visibility in Clinical Trials
13.8.3 Patient Recruitment During And Beyond A COVID-19 World
13.8.4 Patient Data Collection From The Safety Of Patients’ Homes
13.8.5 Key Technologies
13.9 Importance of Logistics Partner for the Success of DTP Model
13.9.1 How the DTP Logistics Model Works?
13.9.2 Coordinating Drug And Lab Sample Deliveries
13.9.3 Single Clinical Logistics Provider Creates Unique Opportunities For Their Clients
13.9.4 Partnering With Global Clinical Logistics Provider is the Key to Success
13.9.5 DTP Maximises The Use Of Supplies, And Minimizes Waste And Shipping Costs
13.9.6 Pandemic Has Disrupted The Clinical Trials Landscape, Creating New Challenges for Logistics
13.9.7 Clinical Trial Professionals And Their Partners Are Seeking Solutions That Help Them Move Forward
13.9.8 The Supply Chain and Trial Design
13.9.9 Return Logistics Is Challenging For Any Clinical Trial, But Even More So In Siteless/Hybrid Trials
13.10 Sponsors Perception Towards DTP Clinical Trial Models
13.10.1 Flexibility Became An Immediate Need For Sponsors, CROs, Clinical Sites, And Patients
13.10.2 Competition for Patients
13.10.3 Competition for Investigator Sites
13.10.4 Commercial Considerations for Sponsors
13.10.5 DTP Can Open Up Sponsors To New Risks In Addition To Those Found In The Conventional Model
13.10.6 The Cornerstones Of All DTP Deployments Must Be Considered Before A Go Ahead
13.10.7 DTP Adoption Could Result in Overall Cost Reduction
13.10.8 Sponsors Should Work In Collaboration With The Sites To Design Effective Strategies To Manage Both Ongoing And New Studies
13.10.9 The Sponsor Should Identify The Mechanism For IMP-Confirmation Of Accountability, Temperature Control Management
13.11 Factors Driving DTP Model Adoption
13.11.1 Nursing Support Is Integral To The Successful Design And Execution Of DTP Model
13.11.2 Patient Centricity and the Growing Interest in Siteless/Hybrid Trials
13.11.3 There Is Considerable Country-To-Country Variation In DTP Regulations
13.11.4 DTP Supports The Swift Enrolments And Strong Retention That Improve Adherence To Overall Study Timelines And Budgets
13.11.5 DTP Has Become An Increasingly Routine Part Of Drug Development In The Post-Pandemic Period
13.11.6 Implement DTP/DFP and HHC services in ongoing clinical trials
13.12 Checkpoints Before Opting for DTP Model for Clinical Trials
13.12.1 Vendors With Access To Patient Information Should Be Audited To Ensure They Are Following All Local Privacy Laws
13.12.2 Risk Mitigation Is Possible When DTP Is Used As An Enabling Component In The Decentralization Of Clinical Trials.
13.12.3 Shift Protocol Design To Leverage Virtual Trials Before Launching New Trials
13.12.4 Patients Participating In A Clinical Trial Have To Deal With A Whole New Set Of Fears
13.12.5 Ensure Clinical Trial Supplies Management
13.13 Global Market Size Estimation and Forecast by Model
13.13.1 Pre-COVID-19 Market Scenario
13.13.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
14 North America Direct-to-Patient Market Analysis
14.1 North America Market Outlook
14.1.1 Rising Prevalence Of Chronic Illnesses And The Growing Desire For In-Home Care Are Two Important Contributors
14.1.2 Presence of Multinational DtP Companies in the Region
14.2 North America Market Size Estimation and Forecast
14.2.1 Pre-COVID-19 Market Scenario
14.2.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
14.3 Regional Market Size Estimation and Forecast
14.3.1 Pre-COVID-19 Market Scenario
14.3.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
14.4 North America Market Size Estimation and Forecast by Type
14.4.1 Pre-COVID-19 Market Scenario
14.4.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
14.5 North America Market Size Estimation and Forecast by Marketing
14.5.1 Pre-COVID-19 Market Scenario
14.5.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
14.6 North America Market Size Estimation and Forecast by Health Services
14.6.1 Pre-COVID-19 Market Scenario
14.6.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
14.7 North America Market Size Estimation and Forecast by Clinical Trials
14.7.1 Pre-COVID-19 Market Scenario
14.7.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
14.8 North America Market Size Estimation and Forecast by Logistics
14.8.1 Pre-COVID-19 Market Scenario
14.8.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
14.9 North America Market Size Estimation and Forecast by Therapeutics
14.9.1 Pre-COVID-19 Market Scenario
14.9.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
14.10 North America Market Size Estimation and Forecast by Model
14.10.1 Pre-COVID-19 Market Scenario
14.10.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
14.11 U.S. Direct-to-Patient Market Analysis
14.11.1 Increasing Healthcare Cost Anticipated to Fuel Telehealth Adoption Rate
14.11.2 US Regulations for DTP Companies
14.11.3 Pre-COVID-19 Market Scenario
14.11.4 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
14.12 Canada Direct-to-Patient Market Analysis
14.12.1 The Growing Inclination For Home And Remote Monitoring
14.12.2 Pre-COVID-19 Market Scenario
14.12.3 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
14.13 Mexico Direct-to-Patient Market Analysis
14.13.1 Patient Monitoring Demand Is Predicted To Expand At A High Rate Throughout The Projection Period
14.13.2 The Direct-To-Patient Nursing Assists the Patient In Overcoming The Hurdles
14.13.3 Pre-COVID-19 Market Scenario
14.13.4 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
15 Europe Direct-to-Patient Market Analysis
15.1.1 Large Investment in Infrastructure for Clinical Research
15.1.2 How DtP is Helping For Innovation in Clinical Trials
15.2 Europe Market Size Estimation and Forecast
15.2.1 Pre-COVID-19 Market Scenario
15.2.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
15.3 Europe Market Size Estimation and Forecast by Country
15.3.1 Pre-COVIountryD-19 Market Scenario
15.3.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
15.4 Europe Market Size Estimation and Forecast by Type
15.4.1 Pre-COVID-19 Market Scenario
15.4.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
15.5 Europe Market Size Estimation and Forecast by Marketing
15.5.1 Pre-COVID-19 Market Scenario
15.5.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
15.6 Europe Market Size Estimation and Forecast by Health Services
15.6.1 Pre-COVID-19 Market Scenario
15.6.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
15.7 Europe Market Size Estimation and Forecast by Clinical Trials
15.7.1 Pre-COVID-19 Market Scenario
15.7.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
15.8 Europe Market Size Estimation and Forecast by Logistics
15.8.1 Pre-COVID-19 Market Scenario
15.8.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
15.9 Europe Market Size Estimation and Forecast by Therapeutics
15.9.1 Pre-COVID-19 Market Scenario
15.9.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
15.10 Europe Market Size Estimation and Forecast by Model
15.10.1 Pre-COVID-19 Market Scenario
15.10.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
15.11 Germany Direct-to-Patient Market Analysis
15.11.1 Germany the DTP Market Will Expand Considerably Due To The Favorable Health Reimbursement Policies In
15.11.2 Germany Is Facing Caregiver Shortage
15.11.3 A Multitude Of Telemedical Systems Are Already Being Used
15.11.4 Pre-COVID-19 Market Scenario
15.11.5 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
15.12 UK Direct-to-Patient Market Analysis
15.12.1 Shift in Trend from Hospital Base Care to Home Care
15.12.2 Rise in Old Age Population will Create Opportunities for DTP
15.12.3 Pre-COVID-19 Market Scenario
15.12.4 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
15.13 France Direct-to-Patient Market Analysis
15.13.1 France’s direct-to-patient Service Providers Have Enjoyed Robust Earnings In Recent Years
15.13.2 The direct-to-patient Services Market Is Heavily Fragmented
15.13.3 Pre-COVID-19 Market Scenario
15.13.4 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
15.14 Italy Direct-to-Patient Market Analysis
15.14.1 Increased Market Shares in Italy by Means of an Organic Growth Strategy
15.14.2 Legislation Relating To The Provision Of DTP Services
15.14.3 Pre-COVID-19 Market Scenario
15.14.4 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
15.15 Spain Direct-to-Patient Market Analysis
15.15.1 Spain Has One of the Best Healthcare Systems in the World
15.15.2 Growing Trend Of Alternative And Complementary Medication
15.15.3 Pre-COVID-19 Market Scenario
15.15.4 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
15.16 Rest of Europe Direct-to-Patient Market Analysis
15.16.1 The Demand For DTP Can Grow With Age, Even If People Get Dependent Later In The Generation
15.16.2 Pre-COVID-19 Market Scenario
15.16.3 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
16 Asia-Pacific Direct-to-Patient Market Analysis
16.1 Asia-Pacific Market Outlook
16.2 Asia-Pacific Market Size Estimation and Forecast
16.2.1 Pre-COVID-19 Market Scenario
16.2.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
16.3 Regional Market Size Estimation and Forecast
16.3.1 Pre-COVID-19 Market Scenario
16.3.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
16.4 Asia-Pacific Market Size Estimation and Forecast by Type
16.4.1 Pre-COVID-19 Market Scenario
16.4.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
16.5 Asia-Pacific Market Size Estimation and Forecast by Marketing
16.5.1 Pre-COVID-19 Market Scenario
16.5.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
16.6 Asia-Pacific Market Size Estimation and Forecast by Health Services
16.6.1 Pre-COVID-19 Market Scenario
16.6.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
16.7 Asia-Pacific Market Size Estimation and Forecast by Clinical Trials
16.7.1 Pre-COVID-19 Market Scenario
16.7.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
16.8 Asia-Pacific Market Size Estimation and Forecast by Logistics
16.8.1 Pre-COVID-19 Market Scenario
16.8.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
16.9 Asia-Pacific Market Size Estimation and Forecast by Therapeutics
16.9.1 Pre-COVID-19 Market Scenario
16.9.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
16.10 Asia-Pacific Market Size Estimation and Forecast by Model
16.10.1 Pre-COVID-19 Market Scenario
16.10.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
16.11 China Direct-to-Patient Market Analysis
16.11.1 During the COVID-19 outbreak, the National Health Commission (NHC) in China has promoted the widespread use of DtP
16.11.2 "Direct-To-Patients" Shipment Of Investigational Drugs Was Made Mandetory By The Government
16.11.3 Pre-COVID-19 Market Scenario
16.11.4 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
16.12 India Direct-to-Patient Market Analysis
16.12.1 Healthcare System in the Country is Moving towards DtP Model
16.12.2 India to Become Key Location of Clinical Trials
16.12.3 Shift in Trend from Hospitals to Home Care in the Country
16.12.4 Pre-COVID-19 Market Scenario
16.12.5 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
16.13 Japan Direct-to-Patient Market Analysis
16.13.1 DtP Services Moving Into The Mainstream In Japan
16.13.2 Close Engagement With Patients Is So Far A Largely Unrealised Opportunity For Pharma In Japan
16.13.3 Pre-COVID-19 Market Scenario
16.13.4 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
16.14 South Korea Direct-to-Patient Market Analysis
16.14.1 South Korea Is One Country That Has Recently Achieved Phenomenal Progress Clinical Trials
16.14.2 Korea Is A Country With Unexpectedly Fast Ageing Speed
16.14.3 Pre-COVID-19 Market Scenario
16.14.4 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
16.15 Australia Direct-to-Patient Market Analysis
16.15.1 Australian Government Providing Home Care Packages (HCP)
16.15.2 There Is A Clear Shift To Home Care Services From Institutionalised Care
16.15.3 Australia's Market For Direct-To-Patient Has Seen Remarkable Expansion
16.15.4 Pre-COVID-19 Market Scenario
16.15.5 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
16.16 Rest of Asia-Pacific Direct-to-Patient Market Analysis
16.16.1 An Ageing Population And Ongoing Urbanisation Impacts The Overall Need DtP Serives
16.16.2 The Supply Of Private Healthcare Facilities Is Ill-Balanced
16.16.3 Pre-COVID-19 Market Scenario
16.16.4 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
17 LAMEA Direct-to-Patient Market Analysis
17.1 LAMEA Market Outlook
17.1.1 Technological Advancements in The DTP Market
17.1.2 Introduction of New Value-Based Payment and Care Models
17.2 LAMEA Market Size Estimation and Forecast
17.2.1 Pre-COVID-19 Market Scenario
17.2.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
17.3 Regional Market Size Estimation and Forecast
17.3.1 Pre-COVID-19 Market Scenario
17.3.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
17.4 LAMEA Market Size Estimation and Forecast by Type
17.4.1 Pre-COVID-19 Market Scenario
17.4.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
17.5 LAMEA Market Size Estimation and Forecast by Marketing
17.5.1 Pre-COVID-19 Market Scenario
17.5.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
17.6 LAMEA Market Size Estimation and Forecast by Health Services
17.6.1 Pre-COVID-19 Market Scenario
17.6.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
17.7 LAMEA Market Size Estimation and Forecast by Clinical Trials
17.7.1 Pre-COVID-19 Market Scenario
17.7.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
17.8 LAMEA Market Size Estimation and Forecast By Logistics
17.8.1 Pre-COVID-19 Market Scenario
17.8.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
17.9 LAMEA Market Size Estimation and Forecast by Therapeutics
17.9.1 Pre-COVID-19 Market Scenario
17.9.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
17.10 LAMEA Market Size Estimation and Forecast by Model
17.10.1 Pre-COVID-19 Market Scenario
17.10.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
17.11 Brazil Direct-to-Patient Market Analysis
17.11.1 Population Aging Process Is A Factor That Drives Health Systems Such As DTP
17.11.2 Changes In The Demographic And Epidemiological Profile In Brazil Raise The Need To Adapt The Health Care Model
17.11.3 Pre-COVID-19 Market Scenario
17.11.4 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
17.12 South Africa Direct-to-Patient Market Analysis
17.12.1 Need for Professional Training for DtP Service Providers
17.12.2 Professional DTP Must Be Included In The Patient's Cultural And Family Context At Home
17.12.3 Pre-COVID-19 Market Scenario
17.12.4 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
17.13 Saudi Arabia Direct-to-Patient Market Analysis
17.13.1 The Professional Needs To Be Incorporated Into The Patient's Cultural And Family Environment
17.13.2 The Kingdom of Saudi Arabia Government Is Developing And Improving Healthcare Services Through A Transformation Plan
17.13.3 Pre-COVID-19 Market Scenario
17.13.4 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
17.14 Turkey Direct-to-Patient Market Analysis
17.14.1 Direct To Patient Has A Large Distribution Network That Reaches All Regions Of Turkey
17.14.2 Turkey’s Family Medicine Reform Will Boost Demand for DtP Services in Nearing Future
17.14.3 Pre-COVID-19 Market Scenario
17.14.4 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
17.15 UAE Direct-to-Patient Market Analysis
17.15.1 Home Care Industry in UAE Is A Fast Growing Sector
17.15.2 Growing Demand For Care In The United Arab Emirates
17.15.3 UAE is Moving Towards Telehealth and DtP Models
17.15.4 Pre-COVID-19 Market Scenario
17.15.5 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
17.16 Rest of LAMEA Direct-to-Patient Market Analysis
17.16.1 The Implications For Home Care And Home Health Seemed Significant
17.16.2 Start-ups in the Country May Disrupt the DTP Market
17.16.3 Pre-COVID-19 Market Scenario
17.16.4 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
18 Competitive Landscape Analysis
18.1 Overview
18.2 Company Market Share Analysis
18.3 Key Business Strategy Analysis
18.4 New Product/Service Launch as the Key Business Strategy In the Global Market
18.5 Expansion as the Key Business Strategy In the Global Market
18.6 Mergers & Acquistions as the Key Business Strategy in the Global Market
18.7 Partnership as the Key Business Strategy In the Global Market
19 Leading Company Analysis and Profile
19.1 American Well
19.1.1 Company Snapshot
19.1.2 Company Overview
19.1.3 Company Financial Profile
19.1.4 Company Product Benchmarking
19.1.5 Company Recent Developments
19.2 Teladoc, Inc.
19.2.1 Company Snapshot
19.2.2 Company Overview
19.2.3 Company Financial Profile
19.2.4 Company Product Benchmarking
19.2.5 Company Recent Developments
19.3 Doctor on demand
19.3.1 Company Snapshot
19.3.2 Company Overview
19.3.3 Company Product Benchmarking
19.3.4 Company Recent Developments
19.4 NURX
19.4.1 Company Snapshot
19.4.2 Company Overview
19.4.3 Company Product Benchmarking
19.4.4 Company Recent Developments
19.5 Specialists on Call, Inc.
19.5.1 Company Overview
19.5.2 Company Snapshot
19.5.3 Company Product Benchmarking
19.5.4 Company Recent Developments
19.6 Babylon Health
19.6.1 Company Snapshot
19.6.2 Company Overview
19.6.3 Company Product Benchmarking
19.6.4 Company Recent Developments
19.7 Dictum Health Inc.
19.7.1 Company Snapshot
19.7.2 Company Overview
19.7.3 Company Product Benchmarking
19.7.4 Company Recent Developments
19.8 Doctor Anywhere Pte. Ltd.
19.8.1 Company Snapshot
19.8.2 Company Overview
19.8.3 Company Product Benchmarking
19.8.4 Company Recent Developments
19.9 Practo technologies pvt ltd
19.9.1 Company Snapshot
19.9.2 Company Overview
19.9.3 Company Product Benchmarking
19.9.4 Company Recent Developments
19.10 CitiusTech Inc.
19.10.1 Company Snapshot
19.10.2 Company Overview
19.10.3 Company Product Benchmarking
19.10.4 Company Recent Developments
19.11 HIMS
19.11.1 Company Snapshot
19.11.2 Company Overview
19.11.3 Company Product Benchmarking
19.11.4 Company Recent Developments
19.12 Health Tap
19.12.1 Company Snapshot
19.12.2 Company Overview
19.12.3 Company Product Benchmarking
19.12.4 Company Recent Developments
19.13 Marken
19.13.1 Company Snapshot
19.13.2 Company Overview
19.13.3 Company Product Benchmarking
19.13.4 Company Recent Developments
19.14 HealthPartners, Inc.
19.14.1 Company Snapshot
19.14.2 Company Overview
19.14.3 Company Product Benchmarking
19.14.4 Company Recent Developments
19.15 Access Physicians
19.15.1 Company Snapshot
19.15.2 Company Overview
19.15.3 Company Product Benchmarking
19.15.4 Company Recent Developments
19.16 20/20NOW
19.16.1 Company Snapshot
19.16.2 Company Overview
19.16.3 Company Product Benchmarking
19.16.4 Company Recent Developments
19.17 AGNITY
19.17.1 Company Snapshot
19.17.2 Company Overview
19.17.3 Company Product Benchmarking
19.17.4 Company Recent Developments
19.18 AMD Global Telemedicine
19.18.1 Company Snapshot
19.18.2 Company Overview
19.18.3 Company Product Benchmarking
19.18.4 Company Recent Developments
19.19 Avera eCARE
19.19.1 Company Snapshot
19.19.2 Company Overview
19.19.3 Company Product Benchmarking
19.19.4 Company Recent Developments
19.20 Axs Healthcare
19.20.1 Company Snapshot
19.20.2 Company Overview
19.20.3 Company Product Benchmarking
19.21 Truepill
19.21.1 Company Snapshot
19.21.2 Company Overview
19.21.3 Company Product Benchmarking
19.21.4 Company Recent Developments
19.22 UpScript Health
19.22.1 Company Snapshot
19.22.2 Company Overview
19.22.3 Company Product Benchmarking
19.22.4 Company Recent Developments
20 Conclusion and Recommendations
20.1 Concluding Remarks
20.2 Recommendations for Market Players
List of Tables
Table 1. Global Direct-to-Patient Market Snapshot, 2021 & 2031 (US$Billion, CAGR %)
Table 2. Global Direct-to-Patient Market Forecast, 2021-2031 (USD Mn, AGR (%) CAGR(%))
Table 3. Global Direct-to-Patient Market Forecast, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (V – Shaped Recovery)
Table 4. Global Direct-to-Patient Market Forecast, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (W – Shaped Recovery)
Table 5. Global Direct-to-Patient Market Forecast, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (U – Shaped Recovery)
Table 6. Global Direct-to-Patient Market Forecast, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (L – Shaped Recovery)
Table 7. Global Direct-to-Patient Market by Region, 2021-2031 (USD Mn, AGR (%) CAGR(%))
Table 8. Global Direct-to-Patient Market by Region, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (V – Shaped Recovery)
Table 9. Global Direct-to-Patient Market by Region, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (W – Shaped Recovery)
Table 10. Global Direct-to-Patient Market by Region, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (U – Shaped Recovery)
Table 11. Global Direct-to-Patient Market by Region, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (L – Shaped Recovery)
Table 12. Global Direct-to-Patient Market by Type, 2021-2031 (USD Mn, AGR (%) CAGR(%))
Table 13. Global Direct-to-Patient Market by Type, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (V-Shaped Recovery)
Table 14. Global Direct-to-Patient Market by Type, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (W-Shaped Recovery)
Table 15. Global Direct-to-Patient Market by Type, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (U-Shaped Recovery)
Table 16. Global Direct-to-Patient Market by Type, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (L-Shaped Recovery)
Table 17. Global Direct-to-Patient Market by Marketing, 2021-2031 (USD Mn, AGR (%) CAGR(%))
Table 18. Global Direct-to-Patient Market by Marketing, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (V – Shaped Recovery)
Table 19. Global Direct-to-Patient Market by Marketing, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (W – Shaped Recovery)
Table 20. Global Direct-to-Patient Market by Marketing, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (U – Shaped Recovery)
Table 21. Global Direct-to-Patient Market by Marketing, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (L – Shaped Recovery)
Table 22. Global Direct-to-Patient Market by Health Services, 2021-2031 (USD Mn, AGR (%) CAGR(%))
Table 23. Global Direct-to-Patient Market by Health Services, 2021-2031 (USD Mn, AGR (%) CAGR(%))
Table 24. Global Direct-to-Patient Market by Health Services, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (W – Shaped Recovery)
Table 25. Global Direct-to-Patient Market by Health Services, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (U – Shaped Recovery)
Table 26. Global Direct-to-Patient Market by Health Services, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (L – Shaped Recovery)
Table 27. Global Direct-to-Patient Market by Clinical Trials, 2021-2031 (USD Mn, AGR (%) CAGR(%))
Table 28. Global Direct-to-Patient Market by Clinical Trials, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (V – Shaped Recovery)
Table 29. Global Direct-to-Patient Market by Clinical Trials, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (W – Shaped Recovery)
Table 30. Global Direct-to-Patient Market by Clinical Trials, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (U – Shaped Recovery)
Table 31. Global Direct-to-Patient Market by Clinical Trials, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (L – Shaped Recovery)
Table 32. Global Direct-to-Patient Market Logistics, 2021-2031 (USD Mn, AGR (%) CAGR(%))
Table 33. Global Direct-to-Patient Market Logistics, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (V – Shaped Recovery)
Table 34. Global Direct-to-Patient Market Logistics, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (W – Shaped Recovery)
Table 35. Global Direct-to-Patient Market Logistics, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (U – Shaped Recovery)
Table 36. Global Direct-to-Patient Market Logistics, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (L – Shaped Recovery)
Table 37. Global Direct-to-Patient Market by Therapeutic, 2021-2031 (USD Mn, AGR (%) CAGR(%))
Table 38. Global Direct-to-Patient Market by Therapeutics, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (V – Shaped Recovery)
Table 39. Global Direct-to-Patient Market by Therapeutics, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (W – Shaped Recovery)
Table 40. Global Direct-to-Patient Market by Therapeutics, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (U – Shaped Recovery)
Table 41. Global Direct-to-Patient Market by Therapeutics, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (%) (L – Shaped Recovery)
Table 42. Global Direct-to-Patient Market by Model, 2021-2031 (USD Mn, AGR (%) CAGR(%))
Table 43. Global Direct-to-Patient Market by Model, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (V-Shaped Recovery)
Table 44. Global Direct-to-Patient Market by Type, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (W-Shaped Recovery)
Table 45. Global Direct-to-Patient Market by Model, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (U-Shaped Recovery)
Table 46. Global Direct-to-Patient Market by Model, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (L-Shaped Recovery)
Table 47. North America Direct-to-Patient Market by Value, 2021-2031 (USD Mn, AGR (%) CAGR(%))
Table 48. North America Direct-to-Patient Market by Value, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (V – Shaped Recovery)
Table 49. North America Direct-to-Patient Market by Value, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (W – Shaped Recovery)
Table 50. North America Direct-to-Patient Market by Value, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (U – Shaped Recovery)
Table 51. North America Direct-to-Patient Market by Value, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (L – Shaped Recovery)
Table 52. North America Direct-to-Patient Market by Country, 2021-2031 (USD Mn, AGR (%) CAGR(%))
Table 53. North America Direct-to-Patient Market by Country, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (V – Shaped Recovery)
Table 54. North America Direct-to-Patient Market by Country, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (W – Shaped Recovery)
Table 55. North America Direct-to-Patient Market by Country, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (U – Shaped Recovery)
Table 56. North America Direct-to-Patient Market by Country, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (L – Shaped Recovery)
Table 57. North America Direct-to-Patient Market by Type, 2021-2031 (USD Mn, AGR (%) CAGR(%))
Table 58. North America Direct-to-Patient Market by Type, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (V – Shaped Recovery)
Table 59. North America Direct-to-Patient Market by Type, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (W – Shaped Recovery)
Table 60. North America Direct-to-Patient Market by Type, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (U – Shaped Recovery)
Table 61. North America Direct-to-Patient Market by Type, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (L – Shaped Recovery)
Table 62. North America Direct-to-Patient Market by Marketing, 2021-2031 (USD Mn, AGR (%) CAGR(%))
Table 63. North America Direct-to-Patient Market by Marketing, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (V – Shaped Recovery)
Table 64. North America Direct-to-Patient Market by Marketing, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (W – Shaped Recovery)
Table 65. North America Direct-to-Patient Market by Marketing, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (U – Shaped Recovery)
Table 66. North America Direct-to-Patient Market by Marketing, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (L – Shaped Recovery)
Table 67. North America Direct-to-Patient Market by Health Services, 2021-2031 (USD Mn, AGR (%) CAGR(%))
Table 68. North America Direct-to-Patient Market by Health Services, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (V – Shaped Recovery)
Table 69. North America Direct-to-Patient Market by Health Services, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (W – Shaped Recovery)
Table 70. North America Direct-to-Patient Market by Health Services, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (U – Shaped Recovery)
Table 71. North America Direct-to-Patient Market by Health Services, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (L – Shaped Recovery)
Table 72. North America Direct-to-Patient Market by Clinical Trials, 2021-2031 (USD Mn, AGR (%) CAGR(%))
Table 73. North America Direct-to-Patient Market by Clinical Trials, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (V – Shaped Recovery)
Table 74. North America Direct-to-Patient Market by Clinical Trials, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (W – Shaped Recovery)
Table 75. North America Direct-to-Patient Market by Clinical Trials, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (U – Shaped Recovery)
Table 76. North America Direct-to-Patient Market by Clinical Trials, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (L – Shaped Recovery)
Table 77. North America Direct-to-Patient Market Logistics, 2021-2031 (USD Mn, AGR (%) CAGR(%))
Table 78. North America Direct-to-Patient Market Logistics, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (V – Shaped Recovery)
Table 79. North America Direct-to-Patient Market Logistics, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (W – Shaped Recovery)
Table 80. North America Direct-to-Patient Market Logistics, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (U – Shaped Recovery)
Table 81. North America Direct-to-Patient Market Logistics, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (L – Shaped Recovery)
Table 82. North America Direct-to-Patient Market by Therapeutics, 2021-2031 (USD Mn, AGR (%) CAGR(%))
Table 83. North America Direct-to-Patient Market by Therapeutics, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (V – Shaped Recovery)
Table 84. North America Direct-to-Patient Market by Therapeutics, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (W – Shaped Recovery)
Table 85. North America Direct-to-Patient Market by Therapeutics, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (U – Shaped Recovery)
Table 86. North America Direct-to-Patient Market by Therapeutics, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (L – Shaped Recovery)
Table 87. North America Direct-to-Patient Market by Model, 2021-2031 (USD Mn, AGR (%) CAGR(%))
Table 88. North America Direct-to-Patient Market by Model, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (V-Shaped Recovery)
Table 89. North America Direct-to-Patient Market by Model, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (W-Shaped Recovery)
Table 90. North America Direct-to-Patient Market by Model, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (U-Shaped Recovery)
Table 91. North America Direct-to-Patient Market by Model, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (L-Shaped Recovery)
Table 92. US Direct-to-Patient Market by Value, 2021-2031 (USD Mn, AGR (%) CAGR(%))
Table 93. US Direct-to-Patient Market by Value, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (V – Shaped Recovery)
Table 94. US Direct-to-Patient Market by Value, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (W – Shaped Recovery)
Table 95. US Direct-to-Patient Market by Value, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (U – Shaped Recovery)
Table 96. US Direct-to-Patient Market by Value, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (L – Shaped Recovery)
Table 97. Canada Direct-to-Patient Market by Value, 2021-2031 (USD Mn, AGR (%) CAGR(%))
Table 98. Canada Direct-to-Patient Market by Value, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (V – Shaped Recovery)
Table 99. Canada Direct-to-Patient Market by Value, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (W – Shaped Recovery)
Table 100. Canada Direct-to-Patient Market by Value, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (U – Shaped Recovery)
Table 102. Mexico Direct-to-Patient Market by Value, 2021-2031 (USD Mn, AGR (%) CAGR(%))
Table 103. Mexico Direct-to-Patient Market by Value, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (V – Shaped Recovery)
Table 104. Mexico Direct-to-Patient Market by Value, 2021-2031 (USD Mn, AGR (%) CAGR(%))W – Shaped Recovery)
Table 105. Mexico Direct-to-Patient Market by Value, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (U – Shaped Recovery)
Table 106. Mexico Direct-to-Patient Market by Value, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (L – Shaped Recovery)
Table 107. Europe Direct-to-Patient Market by Value, 2021-2031 (USD Mn, AGR (%) CAGR(%))
Table 108. Europe Direct-to-Patient Market by Value, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (%) (V – Shaped Recovery)
Table 109. Europe Direct-to-Patient Market by Value, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (W – Shaped Recovery)
Table 110. Europe Direct-to-Patient Market by Value, 2021-2031 (USD Mn, AGR (%) CAGR(%))
Table 111. Europe Direct-to-Patient Market by Value, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (L – Shaped Recovery)
Table 112. Europe Direct-to-Patient Market by Country, 2021-2031 (USD Mn, AGR (%) CAGR(%))
Table 113. Europe Direct-to-Patient Market by Country, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (V – Shaped Recovery)
Table 114. Europe Direct-to-Patient Market by Country, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (W – Shaped Recovery)
Table 115. Europe Direct-to-Patient Market by Country, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (U – Shaped Recovery)
Table 116. Europe Direct-to-Patient Market by Country, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (L – Shaped Recovery)
Table 117. Europe Direct-to-Patient Market by Type, 2021-2031 (USD Mn, AGR (%) CAGR(%))
Table 118. Europe Direct-to-Patient Market by Type, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (V – Shaped Recovery)
Table 119. Europe Direct-to-Patient Market by Type, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (W – Shaped Recovery)
Table 120. Europe Direct-to-Patient Market by Type, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (U – Shaped Recovery)
Table 121. Europe Direct-to-Patient Market by Type, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (L – Shaped Recovery)
Table 122. Europe Direct-to-Patient Market by Marketing, 2021-2031 (USD Mn, AGR (%) CAGR(%))
Table 123. Europe Direct-to-Patient Market by Marketing, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (V – Shaped Recovery)
Table 124. Europe Direct-to-Patient Market by Marketing, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (W – Shaped Recovery)
Table 125. Europe Direct-to-Patient Market by Marketing, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (U – Shaped Recovery)
Table 126. Europe Direct-to-Patient Market by Marketing, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (L – Shaped Recovery)
Table 127. Europe Direct-to-Patient Market by Health Services, 2021-2031 (USD Mn, AGR (%) CAGR(%))
Table 128. Europe Direct-to-Patient Market by Health Services, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (V – Shaped Recovery)
Table 129. Europe Direct-to-Patient Market by Health Services, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (W – Shaped Recovery)
Table 130. Europe Direct-to-Patient Market by Health Services, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (U – Shaped Recovery)
Table 131. Europe Direct-to-Patient Market by Health Services, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (L – Shaped Recovery)
Table 132. Europe Direct-to-Patient Market by Clinical Trials, 2021-2031 (USD Mn, AGR (%) CAGR(%))
Table 133. Europe Direct-to-Patient Market by Clinical Trials, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (V – Shaped Recovery)
Table 134. Europe Direct-to-Patient Market by Clinical Trials, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (W – Shaped Recovery)
Table 135. Europe Direct-to-Patient Market by Clinical Trials, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (U – Shaped Recovery)
Table 136. Europe Direct-to-Patient Market by Clinical Trials, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (L – Shaped Recovery)
Table 137. Europe Direct-to-Patient Market Logistics, 2021-2031 (USD Mn, AGR (%) CAGR(%))
Table 138. Europe Direct-to-Patient Market Logistics, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (V – Shaped Recovery)
Table 139. Europe Direct-to-Patient Market Logistics, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (W – Shaped Recovery)
Table 140. Europe Direct-to-Patient Market Logistics, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (U – Shaped Recovery)
Table 141. Europe Direct-to-Patient Market Logistics, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (L – Shaped Recovery)
Table 142. Europe Direct-to-Patient Market by Therapeutics, 2021-2031 (USD Mn, AGR (%) CAGR(%))
Table 143. Europe Direct-to-Patient Market by Therapeutics, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (V – Shaped Recovery)
Table 144. Europe Direct-to-Patient Market by Therapeutics, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (W – Shaped Recovery)
Table 145. Europe Direct-to-Patient Market by Therapeutics, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (U – Shaped Recovery)
Table 146. Europe Direct-to-Patient Market by Therapeutics, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (L – Shaped Recovery)
Table 147. Europe Direct-to-Patient Market by Model, 2021-2031 (USD Mn, AGR (%) CAGR(%))
Table 148. Europe Direct-to-Patient Market by Model, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (V-Shaped Recovery)
Table 149. Europe Direct-to-Patient Market by Model, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (W-Shaped Recovery)
Table 150. Europe Direct-to-Patient Market by Model, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (U-Shaped Recovery)
Table 151. Europe Direct-to-Patient Market by Model, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (L-Shaped Recovery)
Table 152. Germany Direct-to-Patient Market by Value, 2021-2031 (USD Mn, AGR (%) CAGR(%))
Table 153. Germany Direct-to-Patient Market by Value, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (V – Shaped Recovery)
Table 154. Germany Direct-to-Patient Market by Value, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (W – Shaped Recovery)
Table 155. Germany Direct-to-Patient Market by Value, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (U – Shaped Recovery)
Table 156. Germany Direct-to-Patient Market by Value, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (L – Shaped Recovery)
Table 157. UK Direct-to-Patient Market by Value, 2021-2031 (USD Mn, AGR (%) CAGR(%))
Table 158. UK Direct-to-Patient Market by Value, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (V – Shaped Recovery)
Table 159. UK Direct-to-Patient Market by Value, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (W – Shaped Recovery)
Table 160. UK Direct-to-Patient Market by Value, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (U – Shaped Recovery)
Table 161. UK Direct-to-Patient Market by Value, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (L – Shaped Recovery)
Table 162. France Direct-to-Patient Market by Value, 2021-2031 (USD Mn, AGR (%) CAGR(%))
Table 163. France Direct-to-Patient Market by Value, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (V – Shaped Recovery)
Table 164. France Direct-to-Patient Market by Value, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (W – Shaped Recovery)
Table 165. France Direct-to-Patient Market by Value, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (U – Shaped Recovery)
Table 166. France Direct-to-Patient Market by Value, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (L – Shaped Recovery)
Table 167. Italy Direct-to-Patient Market by Value, 2021-2031 (USD Mn, AGR (%) CAGR(%))
Table 168. Italy Direct-to-Patient Market by Value, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (V – Shaped Recovery)
Table 169. Italy Direct-to-Patient Market by Value, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (W – Shaped Recovery)
Table 170. Italy Direct-to-Patient Market by Value, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (U – Shaped Recovery)
Table 171. Italy Direct-to-Patient Market by Value, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (L – Shaped Recovery)
Table 172. Spain Direct-to-Patient Market by Value, 2021-2031 (USD Mn, AGR (%) CAGR(%))
Table 173. Spain Direct-to-Patient Market by Value, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (V – Shaped Recovery)
Table 174. Spain Direct-to-Patient Market by Value, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (W – Shaped Recovery)
Table 175. Spain Direct-to-Patient Market by Value, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (U – Shaped Recovery)
Table 176. Spain Direct-to-Patient Market by Value, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (L – Shaped Recovery)
Table 177. Rest of Europe Direct-to-Patient Market by Value, 2021-2031 (USD Mn, AGR (%) CAGR(%))
Table 178. Rest of Europe Direct-to-Patient Market by Value, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (V – Shaped Recovery)
Table 179. Rest of Europe Direct-to-Patient Market by Value, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (W – Shaped Recovery)
Table 180. Rest of Europe Direct-to-Patient Market by Value, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (U – Shaped Recovery)
Table 181. Rest of Europe Direct-to-Patient Market by Value, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (L – Shaped Recovery)
Table 182. Asia-Pacific Direct-to-Patient Market by Value, 2021-2031 (USD Mn, AGR (%) CAGR(%))
Table 183. Asia-Pacific Direct-to-Patient Market by Value, 2021-2031 (USD Mn, AGR (%) CAGR(%))V – Shaped Recovery)
Table 184. Asia-Pacific Direct-to-Patient Market by Value, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (W – Shaped Recovery)
Table 185. Asia-Pacific Direct-to-Patient Market by Value, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (U – Shaped Recovery)
Table 186. Asia-Pacific Direct-to-Patient Market by Value, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (L – Shaped Recovery)
Table 187. Asia-Pacific Direct-to-Patient Market by Country, 2021-2031 (USD Mn, AGR (%) CAGR(%))
Table 188. Asia-Pacific Direct-to-Patient Market by Country, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (V – Shaped Recovery)
Table 189. Asia-Pacific Direct-to-Patient Market by Country, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (W – Shaped Recovery)
Table 190. Asia-Pacific Direct-to-Patient Market by Country, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (U – Shaped Recovery)
Table 191. Asia-Pacific Direct-to-Patient Market by Country, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (L – Shaped Recovery)
Table 192. Asia-Pacific Direct-to-Patient Market by Type, 2021-2031 (USD Mn, AGR (%) CAGR(%))
Table 193. Asia-Pacific Direct-to-Patient Market by Type, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (V – Shaped Recovery)
Table 194. Asia-Pacific Direct-to-Patient Market by Type, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (W – Shaped Recovery)
Table 195. Asia-Pacific Direct-to-Patient Market by Type, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (U – Shaped Recovery)
Table 196. Asia-Pacific Direct-to-Patient Market by Type, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (L – Shaped Recovery)
Table 197. Asia-Pacific Direct-to-Patient Market by Marketing, 2021-2031 (USD Mn, AGR (%) CAGR(%))
Table 198. Asia-Pacific Direct-to-Patient Market by Marketing, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (V – Shaped Recovery)
Table 199. Asia-Pacific Direct-to-Patient Market by Marketing, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (W – Shaped Recovery)
Table 200. Asia-Pacific Direct-to-Patient Market by Marketing, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (U – Shaped Recovery)
Table 201. Asia-Pacific Direct-to-Patient Market by Marketing, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (L – Shaped Recovery)
Table 202. Asia-Pacific Direct-to-Patient Market by Health Services, 2021-2031 (USD Mn, AGR (%) CAGR(%))
Table 203. Asia-Pacific Direct-to-Patient Market by Health Services, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (V – Shaped Recovery)
Table 204. Asia-Pacific Direct-to-Patient Market by Health Services, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (W – Shaped Recovery)
Table 205. Asia-Pacific Direct-to-Patient Market by Health Services, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (U – Shaped Recovery)
Table 206. Asia-Pacific Direct-to-Patient Market by Health Services, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (L – Shaped Recovery)
Table 207. Asia-Pacific Direct-to-Patient Market by Clinical Trials, 2021-2031 (USD Mn, AGR (%) CAGR(%))
Table 208. Asia-Pacific Direct-to-Patient Market by Clinical Trials, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (V – Shaped Recovery)
Table 209. Asia-Pacific Direct-to-Patient Market by Clinical Trials, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (W – Shaped Recovery)
Table 210. Asia-Pacific Direct-to-Patient Market by Clinical Trials, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (U – Shaped Recovery)
Table 211. Asia-Pacific Direct-to-Patient Market by Clinical Trials, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (L – Shaped Recovery)
Table 212. Asia-Pacific Direct-to-Patient Market Logistics, 2021-2031 (USD Mn, AGR (%) CAGR(%))
Table 213. Asia-Pacific Direct-to-Patient Market Logistics, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (V – Shaped Recovery)
Table 214. Asia-Pacific Direct-to-Patient Market Logistics, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (W – Shaped Recovery)
Table 215. Asia-Pacific Direct-to-Patient Market Logistics, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (U – Shaped Recovery)
Table 216. Asia-Pacific Direct-to-Patient Market Logistics, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (L – Shaped Recovery)
Table 217. Asia-Pacific Direct-to-Patient Market by Therapeutics, 2021-2031 (USD Mn, AGR (%) CAGR(%))
Table 218. Asia-Pacific Direct-to-Patient Market by Therapeutics, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (V – Shaped Recovery)
Table 219. Asia-Pacific Direct-to-Patient Market by Therapeutics, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (W – Shaped Recovery)
Table 220. Asia-Pacific Direct-to-Patient Market by Therapeutics, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (U – Shaped Recovery)
Table 221. Asia-Pacific Direct-to-Patient Market by Therapeutics, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (L – Shaped Recovery)
Table 222. Asia-Pacific Direct-to-Patient Market by Model, 2021-2031 (USD Mn, AGR (%) CAGR(%))
Table 223. Asia-Pacific Direct-to-Patient Market by Model, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (V-Shaped Recovery)
Table 224. Asia-Pacific Direct-to-Patient Market by Model, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (W-Shaped Recovery)
Table 225. Asia-Pacific Direct-to-Patient Market by Model, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (U-Shaped Recovery)
Table 226. Asia-Pacific Direct-to-Patient Market by Model, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (L-Shaped Recovery)
Table 227. China Direct-to-Patient Market by Value, 2021-2031 (USD Mn, AGR (%) CAGR(%))
Table 228. China Direct-to-Patient Market by Value, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (V – Shaped Recovery)
Table 229. China Direct-to-Patient Market by Value, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (W – Shaped Recovery)
Table 230. China Direct-to-Patient Market by Value, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (U – Shaped Recovery)
Table 231. China Direct-to-Patient Market by Value, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (L – Shaped Recovery)
Table 232. India Direct-to-Patient Market by Value, 2021-2031 (USD Mn, AGR (%) CAGR(%))
Table 233. India Direct-to-Patient Market by Value, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (V – Shaped Recovery)
Table 234. India Direct-to-Patient Market by Value, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (W – Shaped Recovery)
Table 235. India Direct-to-Patient Market by Value, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (U – Shaped Recovery)
Table 236. India Direct-to-Patient Market by Value, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (L – Shaped Recovery)
Table 237. Japan Direct-to-Patient Market by Value, 2021-2031 (USD Mn, AGR (%) CAGR(%))
Table 238. Japan Direct-to-Patient Market by Value, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (V – Shaped Recovery)
Table 239. Japan Direct-to-Patient Market by Value, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (W – Shaped Recovery)
Table 240. Japan Direct-to-Patient Market by Value, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (U – Shaped Recovery)
Table 241. Japan Direct-to-Patient Market by Value, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (L – Shaped Recovery)
Table 242. South Korea Direct-to-Patient Market by Value, 2021-2031 (USD Mn, AGR (%) CAGR(%))
Table 243. South Korea Direct-to-Patient Market by Value, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (V – Shaped Recovery)
Table 244. South Korea Direct-to-Patient Market by Value, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (W – Shaped Recovery)
Table 245. South Korea Direct-to-Patient Market by Value, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (U – Shaped Recovery)
Table 246. South Korea Direct-to-Patient Market by Value, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (L – Shaped Recovery)
Table 247. Australia Direct-to-Patient Market by Value, 2021-2031 (USD Mn, AGR (%) CAGR(%))
Table 248. Australia Direct-to-Patient Market by Value, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (V – Shaped Recovery)
Table 249. Australia Direct-to-Patient Market by Value, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (W – Shaped Recovery)
Table 250. Australia Direct-to-Patient Market by Value, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (U – Shaped Recovery)
Table 251. Australia Direct-to-Patient Market by Value, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (L – Shaped Recovery)
Table 252. Rest of Asia-Pacific Direct-to-Patient Market by Value, 2021-2031 (USD Mn, AGR (%) CAGR(%))
Table 253. Rest of Asia-Pacific Direct-to-Patient Market by Value, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (V – Shaped Recovery)
Table 254. Rest of Asia-Pacific Direct-to-Patient Market by Value, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (W – Shaped Recovery)
Table 255. Rest of Asia-Pacific Direct-to-Patient Market by Value, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (U – Shaped Recovery)
Table 256. Rest of Asia-Pacific Direct-to-Patient Market by Value, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (L – Shaped Recovery)
Table 257. LAMEA Direct-to-Patient Market by Value, 2021-2031 (USD Mn, AGR (%) CAGR(%))
Table 258. LAMEA Direct-to-Patient Market by Value, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (V – Shaped Recovery)
Table 259. LAMEA Direct-to-Patient Market by Value, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (W – Shaped Recovery)
Table 260. LAMEA Direct-to-Patient Market by Value, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (U – Shaped Recovery)
Table 261. LAMEA Direct-to-Patient Market by Value, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (L – Shaped Recovery)
Table 263. LAMEA Direct-to-Patient Market by Country, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (V – Shaped Recovery)
Table 264. LAMEA Direct-to-Patient Market by Country, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (W – Shaped Recovery)
Table 265. LAMEA Direct-to-Patient Market by Country, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (U – Shaped Recovery)
Table 266. LAMEA Direct-to-Patient Market by Country, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (L – Shaped Recovery)
Table 267. LAMEA Direct-to-Patient Market by Type, 2021-2031 (USD Mn, AGR (%) CAGR(%))
Table 268. LAMEA Direct-to-Patient Market by Type, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (V-Shaped Recovery)
Table 269. LAMEA Direct-to-Patient Market by Type, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (W-Shaped Recovery)
Table 270. LAMEA Direct-to-Patient Market by Type, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (U-Shaped Recovery)
Table 271. LAMEA Direct-to-Patient Market by Type, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (L-Shaped Recovery)
Table 272. LAMEA Direct-to-Patient Market by Marketing, 2021-2031 (USD Mn, AGR (%) CAGR(%))
Table 273. LAMEA Direct-to-Patient Market by Marketing, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (V – Shaped Recovery)
Table 274. LAMEA Direct-to-Patient Market by Marketing, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (W – Shaped Recovery)
Table 275. LAMEA Direct-to-Patient Market by Marketing, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (U – Shaped Recovery)
Table 276. LAMEA Direct-to-Patient Market by Marketing, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (L – Shaped Recovery)
Table 277. LAMEA Direct-to-Patient Market by Health Services, 2021-2031 (USD Mn, AGR (%) CAGR(%))
Table 278. LAMEA Direct-to-Patient Market by Health Services, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (V – Shaped Recovery)
Table 279. LAMEA Direct-to-Patient Market by Health Services, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (W – Shaped Recovery)
Table 280. LAMEA Direct-to-Patient Market by Health Services, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (U – Shaped Recovery)
Table 281. LAMEA Direct-to-Patient Market by Health Services, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (L – Shaped Recovery)
Table 282. LAMEA Direct-to-Patient Market by Clinical Trials, 2021-2031 (USD Mn, AGR (%) CAGR(%))
Table 283. LAMEA Direct-to-Patient Market by Clinical Trials, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (V – Shaped Recovery)
Table 284. LAMEA Direct-to-Patient Market by Clinical Trials, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (W – Shaped Recovery)
Table 285. LAMEA Direct-to-Patient Market by Clinical Trials, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (U – Shaped Recovery)
Table 286. LAMEA Direct-to-Patient Market by Clinical Trials, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (L – Shaped Recovery)
Table 287. LAMEA Direct-to-Patient Market Logistics, 2021-2031 (USD Mn, AGR (%) CAGR(%))
Table 288. LAMEA Direct-to-Patient Market Logistics, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (V – Shaped Recovery)
Table 289. LAMEA Direct-to-Patient Market Logistics, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (W – Shaped Recovery)
Table 290. LAMEA Direct-to-Patient Market Logistics, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (U – Shaped Recovery)
Table 291. LAMEA Direct-to-Patient Market Logistics, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (L – Shaped Recovery)
Table 292. LAMEA Direct-to-Patient Market by Therapeutics, 2021-2031 (USD Mn, AGR (%) CAGR(%))
Table 293. LAMEA Direct-to-Patient Market by Therapeutics, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (V – Shaped Recovery)
Table 294. LAMEA Direct-to-Patient Market by Therapeutics, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (W – Shaped Recovery)
Table 295. LAMEA Direct-to-Patient Market by Therapeutics, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (U – Shaped Recovery)
Table 296. LAMEA Direct-to-Patient Market by Therapeutics, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (L – Shaped Recovery)
Table 297. LAMEA Direct-to-Patient Market by Model, 2021-2031 (USD Mn, AGR (%) CAGR(%))
Table 298. LAMEA Direct-to-Patient Market by Model, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (V-Shaped Recovery)
Table 299. LAMEA Direct-to-Patient Market by Model, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (W-Shaped Recovery)
Table 300. LAMEA Direct-to-Patient Market by Model, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (U-Shaped Recovery)
Table 301. LAMEA Direct-to-Patient Market by Model, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (L-Shaped Recovery)
Table 302. Brazil Direct-to-Patient Market by Value, 2021-2031 (USD Mn, AGR (%) CAGR(%))
Table 303. Brazil Direct-to-Patient Market by Value, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (V – Shaped Recovery)
Table 304. Brazil Direct-to-Patient Market by Value, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (W – Shaped Recovery)
Table 305. Brazil Direct-to-Patient Market by Value, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (U – Shaped Recovery)
Table 306. Brazil Direct-to-Patient Market by Value, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (L – Shaped Recovery)
Table 307. South Africa Direct-to-Patient Market by Value, 2021-2031 (USD Mn, AGR (%) CAGR(%))
Table 308. South Africa Direct-to-Patient Market by Value, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (V – Shaped Recovery)
Table 309. South Africa Direct-to-Patient Market by Value, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (W – Shaped Recovery)
Table 310. South Africa Direct-to-Patient Market by Value, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (U – Shaped Recovery)
Table 311. South Africa Direct-to-Patient Market by Value, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (L – Shaped Recovery)
Table 312. Saudi Arabia Direct-to-Patient Market by Value, 2021-2031 (USD Mn, AGR (%) CAGR(%))
Table 313. Saudi Arabia Direct-to-Patient Market by Value, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (V – Shaped Recovery)
Table 314. Saudi Arabia Direct-to-Patient Market by Value, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (W – Shaped Recovery)
Table 315. Saudi Arabia Direct-to-Patient Market by Value, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (U – Shaped Recovery)
Table 316. Saudi Arabia Direct-to-Patient Market by Value, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (L – Shaped Recovery)
Table 317. Turkey Direct-to-Patient Market by Value, 2021-2031 (USD Mn, AGR (%) CAGR(%))
Table 318. Turkey Direct-to-Patient Market by Value, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (V – Shaped Recovery)
Table 319. Turkey Direct-to-Patient Market by Value, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (W – Shaped Recovery)
Table 320. Turkey Direct-to-Patient Market by Value, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (U – Shaped Recovery)
Table 321. Turkey Direct-to-Patient Market by Value, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (L – Shaped Recovery)
Table 322. UAE Direct-to-Patient Market by Value, 2021-2031 (USD Mn, AGR (%) CAGR(%))
Table 323. UAE Direct-to-Patient Market by Value, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (V – Shaped Recovery)
Table 324. UAE Direct-to-Patient Market by Value, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (W – Shaped Recovery)
Table 325. UAE Direct-to-Patient Market by Value, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (U – Shaped Recovery)
Table 326. UAE Direct-to-Patient Market by Value, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (L – Shaped Recovery)
Table 327. Rest of LAMEA Direct-to-Patient Market by Value, 2021-2031 (USD Mn, AGR (%) CAGR(%))
Table 328. Rest of LAMEA Direct-to-Patient Market by Value, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (V – Shaped Recovery)
Table 329. Rest of LAMEA Direct-to-Patient Market by Value, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (W – Shaped Recovery)
Table 330. Rest of LAMEA Direct-to-Patient Market by Value, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (U – Shaped Recovery)
Table 331. Rest of LAMEA Direct-to-Patient Market by Value, 2021-2031 (USD Mn, AGR (%) CAGR(%)) (L – Shaped Recovery)
Table 332. New Product/Service Launch Strategy Adopted by Key Players in Global Direct-to-Patient Market, 2018-2021
Table 333. Expansion Strategy Adopted by Key Players in Global Direct-to-Patient Market, 2018-2021
Table 334. Mergers & Acquisition Strategy Adopted by Key Players in Global Direct-to-Patient Market, 2018-2021
Table 335. Partnership Strategy Adopted by Key Players in Global Direct-to-Patient Market, 2018-2021
Table 336. American Well : Company Information
Table 337. American Well : Company Revenue 2018-2020 (US$Mn, AGR %)
Table 338. American Well : Company Product and Service Benchmarking
Table 339. American Well : Company Recent Developments till Feb, 2021
Table 340. Teladoc, Inc. : Company Information
Table 341. Teladoc, Inc. : Company Revenue 2016-2020 (US$Mn, AGR %)
Table 342. Teladoc, Inc. : Company Product and Service Benchmarking
Table 343. Teladoc, Inc. : Company Recent Developments till Feb, 2021
Table 344. Doctor on demand: Company Information
Table 345. Doctor on demand: Company Product and Service Benchmarking
Table 346. Doctor on demand: Company Recent Developments till Feb, 2021
Table 347. NURX: Company Information
Table 348. NURX: Company Product and Service Benchmarking
Table 349. NURX: Company Recent Developments till Feb, 2021
Table 350. Specialists On Call, Inc.: Company Information
Table 351. Specialists On Call, Inc.: Company Product and Service Benchmarking
Table 352. Specialists On Call, Inc.: Company Recent Developments till Feb, 2021
Table 353. Babylon Health: Company Information
Table 354. Babylon Health: Company Product and Service Benchmarking
Table 355. Babylon Health: Company Recent Developments till Feb, 2021
Table 356. Dictum Health Inc.: Company Information
Table 357. Dictum Health Inc.: Company Product and Service Benchmarking
Table 358. Dictum Health Inc.: Company Recent Developments till Feb, 2021
Table 359. Doctor Anywhere Pte. Ltd.: Company Information
Table 360. Doctor Anywhere Pte. Ltd.: Company Product and Service Benchmarking
Table 361. Doctor Anywhere Pte. Ltd.: Company Recent Developments till Feb, 2021
Table 362. Practo technologies pvt ltd: Company Information
Table 363. Practo technologies pvt ltd: Company Product and Service Benchmarking
Table 364. Practo technologies pvt ltd: Company Recent Developments till Feb, 2021
Table 365. CitiusTech Inc.: Company Information
Table 366. CitiusTech Inc.: Company Product and Service Benchmarking
Table 367. CitiusTech Inc.: Company Recent Developments till Feb, 2021
Table 368. HIMS: Company Information
Table 369. HIMS: Company Product and Service Benchmarking
Table 370. HIMS: Company Recent Developments till Feb, 2021
Table 371. Health Tap: Company Information
Table 372. HealthTap: Company Product and Service Benchmarking
Table 373. HealthTap: Company Recent Developments till Feb, 2021
Table 374. Marken : Company Information
Table 375. Marken : Company Product and Service Benchmarking
Table 376. Marken : Company Recent Developments till Feb, 2021
Table 377. HealthPartners, Inc.: Company Information
Table 378. HealthPartners, Inc.: Company Product and Service Benchmarking
Table 379. HealthPartners, Inc.: Company Recent Developments till Feb, 2021
Table 380. Access Physicians: Company Information
Table 381. Access Physicians: Company Product and Service Benchmarking
Table 382. Access Physicians: Company Recent Developments till Feb, 2021
Table 383. 20/20NOW : Company Information
Table 384. 20/20NOW : Company Product and Service Benchmarking
Table 385. 20/20NOW : Company Recent Developments till Feb, 2021
Table 386. AGNITY: Company Information
Table 387. AGNITY: Company Product and Service Benchmarking
Table 388. AGNITY: Company Recent Developments till Feb, 2021
Table 389. AMD Global Telemedicine : Company Information
Table 390. AMD Global Telemedicine : Company Product and Service Benchmarking
Table 391. AMD Global Telemedicine : Company Recent Developments till Feb, 2021
Table 392. Avera eCARE: Company Information
Table 393. Avera eCARE: Company Product and Service Benchmarking
Table 394. Avera eCARE: Company Recent Developments till Feb, 2021
Table 395. Axs Healthcare: Company Information
Table 396. Axs Healthcare: Company Product and Service Benchmarking
Table 397. Truepill : Company Information
Table 398. Truepill : Company Product and Service Benchmarking
Table 399. Truepill : Company Recent Developments till Feb, 2021
Table 400. UpScript Health: Company Information
Table 401. UpScript Health: Company Product and Service Benchmarking
Table 402. UpScript Health: Company Recent Developments till Feb, 2021
List of Figures
Figure 1. Global Direct-to-Patient Market Segmentation
Figure 2. Direct-to-Patient Collaborative Approach
Figure 3. Two Temperature Monitoring Options for Clinical Supply Chains
Figure 4. Difficulties in Managing Data in DtP Model
Figure 5. Direct to Patient Clinical Supply Chains
Figure 6. Drivers, Restraints, Opportunities and Challenges in the Global DPT Market
Figure 7. Porter’s Five Forces Model of Direct-to-Patient Market
Figure 8. Global Direct To Patient Market Forecast, 2021-2031 (USD Mn, AGR (%)
Figure 9. Global Direct-to-Patient Market Forecast, 2021-2031 (USD Mn, AGR (%) (V – Shaped Recovery)
Figure 10. Global Direct To Patient Market Forecast, 2021-2031 (USD Mn, AGR (%) (W – Shaped Recovery)
Figure 11. Global Direct To Patient Market Forecast 2021-2031 (USD Mn, AGR (%) (U – Shaped Recovery)
Figure 12. Global Direct To Patient Market Forecast 2021-2031 (USD Mn, AGR (%) (L – Shaped Recovery)
Figure 13. Global Direct-to-Patient Market by Region 2021, 2026, 2031 (%)
Figure 14. Global Direct To Patient Market by Region, 2021-2031 (USD Mn, AGR (%)
Figure 15. Global Direct To Patient Market by Region, 2021-2031 (USD Mn, AGR (%) (V – Shaped Recovery)
Figure 16. Global Direct To Patient Market by Region, 2021-2031 (USD Mn, AGR (%) (W – Shaped Recovery)
Figure 17. Global Direct To Patient Market by Region, 2021-2031 (USD Mn, AGR (%) (U – Shaped Recovery)
Figure 18. Global Direct To Patient Market by Region, 2021-2031 (USD Mn, AGR (%) (L – Shaped Recovery)
Figure 19. Global Direct-to-Patient Market by Type 2021, 2026, 2031 (%)
Figure 20. Global Direct To Patient Market by Type, 2021-2031 (USD Mn, AGR (%)
Figure 21. Global Direct To Patient Market by Type, 2021-2031 (USD Mn, AGR (%) (V-Shaped Recovery)
Figure 22. Global Direct To Patient Market by Type, 2021-2031 (USD Mn, AGR (%) (W-Shaped Recovery)
Figure 23. Global Direct To Patient Market by Type, 2021-2031 (USD Mn, AGR (%) (U-Shaped Recovery)
Figure 24. Global Direct To Patient Market by Type, 2021-2031 (USD Mn, AGR (%) (L-Shaped Recovery)
Figure 25. Global Direct-to-Patient Market by Marketing 2021, 2026, 2031 (%)
Figure 26. Global Direct To Patient Market by Marketing , 2021-2031 (USD Mn, AGR (%)
Figure 27. Global Direct To Patient Market by Marketing , 2021-2031 (USD Mn, AGR (%) (V – Shaped Recovery)
Figure 28. Global Direct To Patient Market by Marketing , 2021-2031 (USD Mn, AGR (%) (W – Shaped Recovery)
Figure 29. Global Direct To Patient Market by Marketing , 2021-2031 (USD Mn, AGR (%) (U – Shaped Recovery)
Figure 30. Global Direct To Patient Market by Marketing , 2021-2031 (USD Mn, AGR (%) (L – Shaped Recovery)
Figure 31. Global Direct-to-Patient Market by Health Services 2021, 2026, 2031 (%)
Figure 32. Global Direct To Patient Market by Health Services, 2021-2031 (USD Mn, AGR (%)
Figure 33. Global Direct To Patient Market by Health Services, 2021-2031 (USD Mn, AGR (%) (V – Shaped Recovery)
Figure 34. Global Direct To Patient Market by Health Services, 2021-2031 (USD Mn, AGR (%) (W – Shaped Recovery)
Figure 35. Global Direct To Patient Market by Health Services, 2021-2031 (USD Mn, AGR (%) (U – Shaped Recovery)
Figure 36. Global Direct To Patient Market by Health Services, 2021-2031 (USD Mn, AGR (%) (L – Shaped Recovery)
Figure 37. Global Direct-to-Patient Market by Clinical Trials 2021, 2026, 2031 (%)
Figure 38. Global Direct To Patient Market by Clinical Trials , 2021-2031 (USD Mn, AGR (%)
Figure 39. Global Direct To Patient Market by Clinical Trials , 2021-2031 (USD Mn, AGR (%) (V – Shaped Recovery)
Figure 40. Global Direct To Patient Market by Clinical Trials , 2021-2031 (USD Mn, AGR (%) (W – Shaped Recovery)
Figure 41. Global Direct To Patient Market by Clinical Trials , 2021-2031 (USD Mn, AGR (%) (U – Shaped Recovery)
Figure 42. Global Direct To Patient Market by Clinical Trials , 2021-2031 (USD Mn, AGR (%) (L – Shaped Recovery)
Figure 43. Global Direct-to-Patient Market by Logistics 2021, 2026, 2031 (%)
Figure 44. Global Direct To Patient Market Logistics, 2021-2031 (USD Mn, AGR (%)
Figure 45. Global Direct To Patient Market Logistics, 2021-2031 (USD Mn, AGR (%) (V – Shaped Recovery)
Figure 46. Global Direct To Patient Market Logistics, 2021-2031 (USD Mn, AGR (%) (W – Shaped Recovery)
Figure 47. Global Direct To Patient Market Logistics, 2021-2031 (USD Mn, AGR (%) (U – Shaped Recovery)
Figure 48. Global Direct To Patient Market Logistics, 2021-2031 (USD Mn, AGR (%) (L – Shaped Recovery)
Figure 49. Global Direct-to-Patient Market by Therapeutic 2021, 2026, 2031 (%)
Figure 50. Global Direct To Patient Market by Therapeutics, 2021-2031 (USD Mn, AGR (%)
Figure 51. Global Direct To Patient Market by Therapeutics, 2021-2031 (USD Mn, AGR (%) (V – Shaped Recovery)
Figure 52. Global Direct To Patient Market by Therapeutics, 2021-2031 (USD Mn, AGR (%) (W – Shaped Recovery)
Figure 53. Global Direct To Patient Market by Therapeutics, 2021-2031 (USD Mn, AGR (%) (U – Shaped Recovery)
Figure 54. Global Direct To Patient Market by Therapeutics, 2021-2031 (USD Mn, AGR (%) (L – Shaped Recovery)
Figure 55. Global Direct-to-Patient Market by Model 2021, 2026, 2031 (%)
Figure 56. Patient Service Center Overview
Figure 57. Global Direct To Patient Market by Model, 2021-2031 (USD Mn, AGR (%)
Figure 58. Global Direct To Patient Market by Model, 2021-2031 (USD Mn, AGR (%) (V-Shaped Recovery)
Figure 59. Global Direct To Patient Market by Model, 2021-2031 (USD Mn, AGR (%) (W-Shaped Recovery)
Figure 60. Global Direct To Patient Market by Model, 2021-2031 (USD Mn, AGR (%) (U-Shaped Recovery)
Figure 61. Global Direct To Patient Market by Model, 2021-2031 (USD Mn, AGR (%) (L-Shaped Recovery)
Figure 62. North America Direct To Patient Market by Value, 2021-2031 (USD Mn, AGR (%)
Figure 63. North America Direct-to-Patient Market by Value, 2021-2031 (USD Mn, AGR (%) (V – Shaped Recovery)
Figure 64. North America Direct To Patient Market by Value, 2021-2031 (USD Mn, AGR (%) (W – Shaped Recovery)
Figure 65. North America Direct To Patient Market by Value 2021-2031 (USD Mn, AGR (%) (U – Shaped Recovery)
Figure 66. North America Direct To Patient Market, 2021-2031 (USD Mn, AGR (%) CAGR (%)) (L – Shaped Recovery)
Figure 67. North America Direct To Patient Market by Country, 2021-2031 (USD Mn, AGR)
Figure 68. North America Direct To Patient Market by Country, 2021-2031 (USD Mn, AGR (%) (V – Shaped Recovery)
Figure 69. North America Direct To Patient Market by Region, 2021-2031 (USD Mn, AGR (%) (W – Shaped Recovery)
Figure 70. North America Direct To Patient Market by Country, 2021-2031 (USD Mn, AGR (%) (U – Shaped Recovery)
Figure 71. North America Direct To Patient Market by Country, 2021-2031 (USD Mn, AGR (%) (L – Shaped Recovery)
Figure 72. North America Direct To Patient Market by by Type, 2021-2031 (USD Mn, AGR (%)
Figure 73. North America Direct To Patient Market by by Type, 2021-2031 (USD Mn, AGR (%) (V – Shaped Recovery)
Figure 74. North America Direct To Patient Market by by Type, 2021-2031 (USD Mn, AGR (%) (W – Shaped Recovery)
Figure 75. North America Direct To Patient Market by by Type, 2021-2031 (USD Mn, AGR (%) (U – Shaped Recovery)
Figure 76. North America Direct To Patient Market by by Type, 2021-2031 (USD Mn, AGR (%) (L – Shaped Recovery)
Figure 77. North America Direct To Patient Market by Marketing, 2021-2031 (USD Mn, AGR (%)
Figure 78. North America Direct To Patient Market by Marketing , 2021-2031 (USD Mn, AGR (%) (V – Shaped Recovery)
Figure 79. North America Direct To Patient Market by Marketing , 2021-2031 (USD Mn, AGR (%) (W – Shaped Recovery)
Figure 80. North America Direct To Patient Market by Marketing , 2021-2031 (USD Mn, AGR (%) (U – Shaped Recovery)
Figure 81. North America Direct To Patient Market by Marketing , 2021-2031 (USD Mn, AGR (%) (L – Shaped Recovery)
Figure 82. North America Direct To Patient Market by Health Services, 2021-2031 (USD Mn, AGR (%)
Figure 83. North America Direct To Patient Market by Health Services, 2021-2031 (USD Mn, AGR (%) (V – Shaped Recovery)
Figure 84. North America Direct To Patient Market by Health Services, 2021-2031 (USD Mn, AGR (%) (W – Shaped Recovery)
Figure 85. North America Direct To Patient Market by Health Services, 2021-2031 (USD Mn, AGR (%) (U – Shaped Recovery)
Figure 86. North America Direct To Patient Market by Health Services, 2021-2031 (USD Mn, AGR (%) (L – Shaped Recovery)
Figure 87. North America Direct To Patient Market by Clinical Trials , 2021-2031 (USD Mn, AGR (%)
Figure 88. North America Direct To Patient Market by Clinical Trials , 2021-2031 (USD Mn, AGR (%) (V – Shaped Recovery)
Figure 89. North America Direct To Patient Market by Clinical Trials , 2021-2031 (USD Mn, AGR (%) (W – Shaped Recovery)
Figure 90. North America Direct To Patient Market by Clinical Trials , 2021-2031 (USD Mn, AGR (%) (U – Shaped Recovery)
Figure 91. North America Direct To Patient Market by Clinical Trials , 2021-2031 (USD Mn, AGR (%) (L – Shaped Recovery)
Figure 92. North America Direct To Patient Market Logistics, 2021-2031 (USD Mn, AGR (%)
Figure 93. North America Direct To Patient Market Logistics, 2021-2031 (USD Mn, AGR (%) (V – Shaped Recovery)
Figure 94. North America Direct To Patient Market Logistics, 2021-2031 (USD Mn, AGR (%) (W – Shaped Recovery)
Figure 95. North America Direct To Patient Market Logistics, 2021-2031 (USD Mn, AGR (%) (U – Shaped Recovery)
Figure 96. North America Direct To Patient Market Logistics, 2021-2031 (USD Mn, AGR (%) (L – Shaped Recovery)
Figure 97. North America Direct To Patient Market by Therapeutics, 2021-2031 (USD Mn, AGR (%)
Figure 98. North America Direct To Patient Market by Therapeutics, 2021-2031 (USD Mn, AGR (%) (V – Shaped Recovery)
Figure 99. North America Direct To Patient Market by Therapeutics, 2021-2031 (USD Mn, AGR (%) (W – Shaped Recovery)
Figure 100. North America Direct To Patient Market by Therapeutics, 2021-2031 (USD Mn, AGR (%) (U – Shaped Recovery)
Figure 101. North America Direct To Patient Market by Therapeutics, 2021-2031 (USD Mn, AGR (%) (L – Shaped Recovery)
Figure 102. North America Direct To Patient Market by Model, 2021-2031 (USD Mn, AGR (%)
Figure 103. North America Direct To Patient Market by Model, 2021-2031 (USD Mn, AGR (%) (V-Shaped Recovery)
Figure 104. North America Direct To Patient Market by Model, 2021-2031 (USD Mn, AGR (%) (W-Shaped Recovery)
Figure 105. North America Direct To Patient Market by Model, 2021-2031 (USD Mn, AGR (%) (U-Shaped Recovery)
Figure 106. North America Direct To Patient Market by Model, 2021-2031 (USD Mn, AGR (%) (L-Shaped Recovery)
Figure 107. North America Direct-to-Patient Market by Value, 2021-2031 (USD Mn, AGR (%)
Figure 108. US Direct-to-Patient Market by Value, 2021-2031 (USD Mn, AGR (%) (V – Shaped Recovery)
Figure 109. US Direct-to-Patient Market by Value, 2021-2031 (USD Mn, AGR (%) (W – Shaped Recovery)
Figure 110. US Direct-to-Patient Market by Value, 2021-2031 (USD Mn, AGR (%) (U – Shaped Recovery)
Figure 111. US Direct-to-Patient Market by Value, 2021-2031 (USD Mn, AGR (%) (L – Shaped Recovery)
Figure 112. Canada Direct-to-Patient Market by Value, 2021-2031 (USD Mn, AGR (%)
Figure 113. Canada Direct-to-Patient Market by Value, 2021-2031 (USD Mn, AGR (%) (V – Shaped Recovery)
Figure 114. Canada Direct-to-Patient Market by Value, 2021-2031 (USD Mn, AGR (%) (W – Shaped Recovery)
Figure 115. Canada Direct-to-Patient Market by Value, 2021-2031 (USD Mn, AGR (%) (U – Shaped Recovery)
Figure 116. Canada Direct-to-Patient Market by Value, 2021-2031 (USD Mn, AGR (%) (L – Shaped Recovery)
Figure 117. Mexico Direct-to-Patient Market by Value, 2021-2031 (USD Mn, AGR (%)
Figure 118. Mexico Direct-to-Patient Market by Value, 2021-2031 (USD Mn, AGR (%) (%)) (V – Shaped Recovery)
Figure 119. Mexico Direct-to-Patient Market by Value, 2021-2031 (USD Mn, AGR (%) (W – Shaped Recovery)
Figure 120. Mexico Direct-to-Patient Market by Value, 2021-2031 (USD Mn, AGR (%) (U – Shaped Recovery)
Figure 121. Mexico Direct-to-Patient Market by Value, 2021-2031 (USD Mn, AGR (%) (L – Shaped Recovery)
Figure 122. Europe Direct To Patient Market by Value , 2021-2031 (USD Mn, AGR (%)
Figure 123. Europe Direct-to-Patient Market by Value, 2021-2031 (USD Mn, AGR (%) (V – Shaped Recovery)
Figure 124. Europe Direct To Patient Market by Value , 2021-2031 (USD Mn, AGR (%) (W – Shaped Recovery)
Figure 125. Europe Direct To Patient Market by Value 2021-2031 (USD Mn, AGR (%) (U – Shaped Recovery)
Figure 126. Europe Direct To Patient Market by Value 2021-2031 (USD Mn, AGR (%) (L – Shaped Recovery)
Figure 127. Europe Direct To Patient Market by Country, 2021-2031 (USD Mn, AGR (%)
Figure 128. Europe Direct To Patient Market by Country, 2021-2031 (USD Mn, AGR (%) (V – Shaped Recovery)
Figure 129. Europe Direct To Patient Market by Country, 2021-2031 (USD Mn, AGR (%) (W – Shaped Recovery)
Figure 130. Europe Direct To Patient Market by Country, 2021-2031 (USD Mn, AGR (%) (U – Shaped Recovery)
Figure 131. Europe Direct To Patient Market by Country, 2021-2031 (USD Mn, AGR (%) (L – Shaped Recovery)
Figure 132. Europe Direct To Patient Market by by Type, 2021-2031 (USD Mn, AGR (%)
Figure 133. Europe Direct To Patient Market by by Type, 2021-2031 (USD Mn, AGR (%) (V – Shaped Recovery)
Figure 134. Europe Direct To Patient Market by by Type, 2021-2031 (USD Mn, AGR (%) (W – Shaped Recovery)
Figure 135. Europe Direct To Patient Market by by Type, 2021-2031 (USD Mn, AGR (%) (U – Shaped Recovery)
Figure 136. Europe Direct To Patient Market by by Type, 2021-2031 (USD Mn, AGR (%) (L – Shaped Recovery)
Figure 137. Europe Direct To Patient Market by Marketing , 2021-2031 (USD Mn, AGR (%)
Figure 138. Europe Direct To Patient Market by Marketing , 2021-2031 (USD Mn, AGR (%) (V – Shaped Recovery)
Figure 139. Europe Direct To Patient Market by Marketing , 2021-2031 (USD Mn, AGR (%) (W – Shaped Recovery)
Figure 140. Europe Direct To Patient Market by Marketing , 2021-2031 (USD Mn, AGR (%) (U – Shaped Recovery)
Figure 141. Europe Direct To Patient Market by Marketing , 2021-2031 (USD Mn, AGR (%) (L – Shaped Recovery)
Figure 142. Europe Direct To Patient Market by Health Services, 2021-2031 (USD Mn, AGR (%)
Figure 143. Europe Direct To Patient Market by Health Services, 2021-2031 (USD Mn, AGR (%) (V – Shaped Recovery)
Figure 144. Europe Direct To Patient Market by Health Services, 2021-2031 (USD Mn, AGR (%) (W – Shaped Recovery)
Figure 145. Europe Direct To Patient Market by Health Services, 2021-2031 (USD Mn, AGR (%) (U – Shaped Recovery)
Figure 146. Europe Direct To Patient Market by Health Services, 2021-2031 (USD Mn, AGR (%) (L – Shaped Recovery)
Figure 147. Europe Direct To Patient Market by Clinical Trials , 2021-2031 (USD Mn, AGR (%)
Figure 148. Europe Direct To Patient Market by Clinical Trials , 2021-2031 (USD Mn, AGR (%) (V – Shaped Recovery)
Figure 149. Europe Direct To Patient Market by Clinical Trials , 2021-2031 (USD Mn, AGR (%) (W – Shaped Recovery)
Figure 150. Europe Direct To Patient Market by Clinical Trials , 2021-2031 (USD Mn, AGR (%) (U – Shaped Recovery)
Figure 151. Europe Direct To Patient Market by Clinical Trials , 2021-2031 (USD Mn, AGR (%) (L – Shaped Recovery)
Figure 152. Europe Direct To Patient Market Logistics, 2021-2031 (USD Mn, AGR (%)
Figure 153. Europe Direct To Patient Market Logistics, 2021-2031 (USD Mn, AGR (%) (V – Shaped Recovery)
Figure 154. Europe Direct To Patient Market Logistics, 2021-2031 (USD Mn, AGR (%) (W – Shaped Recovery)
Figure 155. Europe Direct To Patient Market Logistics, 2021-2031 (USD Mn, AGR (%) (U – Shaped Recovery)
Figure 156. Europe Direct To Patient Market Logistics, 2021-2031 (USD Mn, AGR (%) (L – Shaped Recovery)
Figure 157. Europe Direct To Patient Market by Therapeutics, 2021-2031 (USD Mn, AGR (%)
Figure 158. Europe Direct To Patient Market by Therapeutics, 2021-2031 (USD Mn, AGR (%) (V – Shaped Recovery)
Figure 159. Europe Direct To Patient Market by Therapeutics, 2021-2031 (USD Mn, AGR (%) (W – Shaped Recovery)
Figure 160. Europe Direct To Patient Market by Therapeutics, 2021-2031 (USD Mn, AGR (%) (U – Shaped Recovery)
Figure 161. Europe Direct To Patient Market by Therapeutics, 2021-2031 (USD Mn, AGR (%) (L – Shaped Recovery)
Figure 162. Europe Direct To Patient Market by Model, 2021-2031 (USD Mn, AGR (%)
Figure 163. Europe Direct To Patient Market by Model, 2021-2031 (USD Mn, AGR (%) (V-Shaped Recovery)
Figure 164. Europe Direct To Patient Market by Model, 2021-2031 (USD Mn, AGR (%) (W-Shaped Recovery)
Figure 165. Europe Direct To Patient Market by Model, 2021-2031 (USD Mn, AGR (%) (U-Shaped Recovery)
Figure 166. Europe Direct To Patient Market by Model, 2021-2031 (USD Mn, AGR (%) (L-Shaped Recovery)
Figure 167. Germany Direct-to-Patient Market by Value, 2021-2031 (USD Mn, AGR (%)
Figure 168. Germany Direct-to-Patient Market by Value, 2021-2031 (USD Mn, AGR (%) (V – Shaped Recovery)
Figure 169. Germany Direct-to-Patient Market by Value, 2021-2031 (USD Mn, AGR (%) (W – Shaped Recovery)
Figure 170. Germany Direct-to-Patient Market by Value, 2021-2031 (USD Mn, AGR (%) (U – Shaped Recovery)
Figure 171. Germany Direct-to-Patient Market by Value, 2021-2031 (USD Mn, AGR (%) (L – Shaped Recovery)
Figure 172. UK Direct-to-Patient Market by Value, 2021-2031 (USD Mn, AGR (%)
Figure 173. UK Direct-to-Patient Market by Value, 2021-2031 (USD Mn, AGR (%) (V – Shaped Recovery)
Figure 174. UK Direct-to-Patient Market by Value, 2021-2031 (USD Mn, AGR (%) (W – Shaped Recovery)
Figure 175. UK Direct-to-Patient Market by Value, 2021-2031 (USD Mn, AGR (%) (U – Shaped Recovery)
Figure 175. UK Direct-to-Patient Market by Value, 2021-2031 (USD Mn, AGR (%) (U – Shaped Recovery)
Figure 177. France Direct-to-Patient Market by Value, 2021-2031 (USD Mn, AGR (%)
Figure 178. France Direct-to-Patient Market by Value, 2021-2031 (USD Mn, AGR (%) (V – Shaped Recovery)
Figure 179. France Direct-to-Patient Market by Value, 2021-2031 (USD Mn, AGR (%) (W – Shaped Recovery)
Figure 180. France Direct-to-Patient Market by Value, 2021-2031 (USD Mn, AGR (%) (U – Shaped Recovery)
Figure 181. France Direct-to-Patient Market by Value, 2021-2031 (USD Mn, AGR (%) (L – Shaped Recovery)
Figure 182. Italy Direct-to-Patient Market by Value, 2021-2031 (USD Mn, AGR (%)
Figure 183. Italy Direct-to-Patient Market by Value, 2021-2031 (USD Mn, AGR (%) (V – Shaped Recovery)
Figure 184. Italy Direct-to-Patient Market by Value, 2021-2031 (USD Mn, AGR (%) (W – Shaped Recovery)
Figure 185. Italy Direct-to-Patient Market by Value, 2021-2031 (USD Mn, AGR (%) (U – Shaped Recovery)
Figure 186. Italy Direct-to-Patient Market by Value, 2021-2031 (USD Mn, AGR (%) (L – Shaped Recovery)
Figure 187. Spain Direct-to-Patient Market by Value, 2021-2031 (USD Mn, AGR (%)
Figure 188. Spain Direct-to-Patient Market by Value, 2021-2031 (USD Mn, AGR (%) (V – Shaped Recovery)
Figure 189. Spain Direct-to-Patient Market by Value, 2021-2031 (USD Mn, AGR (%) (W – Shaped Recovery)
Figure 190. Spain Direct-to-Patient Market by Value, 2021-2031 (USD Mn, AGR (%) (U – Shaped Recovery)
Figure 191. Spain Direct-to-Patient Market by Value, 2021-2031 (USD Mn, AGR (%) (L – Shaped Recovery)
Figure 192. Rest of Europe Direct-to-Patient Market by Value, 2021-2031 (USD Mn, AGR (%)
Figure 193. Rest of Europe Direct-to-Patient Market by Value, 2021-2031 (USD Mn, AGR (%) (V – Shaped Recovery)
Figure 194. Rest of Europe Direct-to-Patient Market by Value, 2021-2031 (USD Mn, AGR (%) (W – Shaped Recovery)
Figure 195. Rest of Europe Direct-to-Patient Market by Value, 2021-2031 (USD Mn, AGR (%) (U – Shaped Recovery)
Figure 196. Rest of Europe Direct-to-Patient Market by Value, 2021-2031 (USD Mn, AGR (%) (L – Shaped Recovery)
Figure 197. Asia-Pacific Direct To Patient Market by Value, 2021-2031 (USD Mn, AGR (%)
Figure 198. Asia-Pacific Direct-to-Patient Market by Value, 2021-2031 (USD Mn, AGR (%) (V – Shaped Recovery)
Figure 199. Asia-Pacific Direct To Patient Market Forecast, 2021-2031 (USD Mn, AGR (%) (W – Shaped Recovery)
Figure 200. Asia-Pacific Direct To Patient Market by Value 2021-2031 (USD Mn, AGR (%) (U – Shaped Recovery)
Figure 201. Asia-Pacific Direct To Patient Market by Value 2021-2031 (USD Mn, AGR (%) (L – Shaped Recovery)
Figure 202. Asia-Pacific Direct To Patient Market by Country, 2021-2031 (USD Mn, AGR (%)
Figure 203. Asia-Pacific Direct To Patient Market by Country, 2021-2031 (USD Mn, AGR (%) (V – Shaped Recovery)
Figure 204. Asia-Pacific Direct To Patient Market by Country, 2021-2031 (USD Mn, AGR (%) (W – Shaped Recovery)
Figure 205. Asia-Pacific Direct To Patient Market by Country, 2021-2031 (USD Mn, AGR (%) (U – Shaped Recovery)
Figure 206. Asia-Pacific Direct To Patient Market by Country, 2021-2031 (USD Mn, AGR (%) (L – Shaped Recovery)
Figure 207. Asia-Pacific Direct To Patient Market by by Type, 2021-2031 (USD Mn, AGR (%)
Figure 208. Asia-Pacific Direct To Patient Market by by Type, 2021-2031 (USD Mn, AGR (%) (V – Shaped Recovery)
Figure 209. Asia-Pacific Direct To Patient Market by by Type, 2021-2031 (USD Mn, AGR (%) (W – Shaped Recovery)
Figure 210. Asia-Pacific Direct To Patient Market by by Type, 2021-2031 (USD Mn, AGR (%) (U – Shaped Recovery)
Figure 211. Asia-Pacific Direct To Patient Market by by Type, 2021-2031 (USD Mn, AGR (%) (L – Shaped Recovery)
Figure 212. Asia-Pacific Direct To Patient Market by Marketing , 2021-2031 (USD Mn, AGR (%)
Figure 213. Asia-Pacific Direct To Patient Market by Marketing , 2021-2031 (USD Mn, AGR (%) (V – Shaped Recovery)
Figure 214. Asia-Pacific Direct To Patient Market by Marketing , 2021-2031 (USD Mn, AGR (%) (W – Shaped Recovery)
Figure 215. Asia-Pacific Direct To Patient Market by Marketing , 2021-2031 (USD Mn, AGR (%) (U – Shaped Recovery)
Figure 216. Asia-Pacific Direct To Patient Market by Marketing , 2021-2031 (USD Mn, AGR (%) (L – Shaped Recovery)
Figure 217. Asia-Pacific Direct To Patient Market by Health Services, 2021-2031 (USD Mn, AGR (%)
Figure 218. Asia-Pacific Direct To Patient Market by Health Services, 2021-2031 (USD Mn, AGR (%) (V – Shaped Recovery)
Figure 219. Asia-Pacific Direct To Patient Market by Health Services, 2021-2031 (USD Mn, AGR (%) (W – Shaped Recovery)
Figure 220. Asia-Pacific Direct To Patient Market by Health Services, 2021-2031 (USD Mn, AGR (%) (U – Shaped Recovery)
Figure 221. Asia-Pacific Direct To Patient Market by Health Services, 2021-2031 (USD Mn, AGR (%) (L – Shaped Recovery)
Figure 222. Asia-Pacific Direct To Patient Market by Clinical Trials , 2021-2031 (USD Mn, AGR (%)
Figure 223. Asia-Pacific Direct To Patient Market by Clinical Trials , 2021-2031 (USD Mn, AGR (%) (V – Shaped Recovery)
Figure 224. Asia-Pacific Direct To Patient Market by Clinical Trials , 2021-2031 (USD Mn, AGR (%) (W – Shaped Recovery)
Figure 225. Asia-Pacific Direct To Patient Market by Clinical Trials , 2021-2031 (USD Mn, AGR (%) (U – Shaped Recovery)
Figure 226. Asia-Pacific Direct To Patient Market by Clinical Trials , 2021-2031 (USD Mn, AGR (%) (L – Shaped Recovery)
Figure 227. Asia-Pacific Direct To Patient Market Logistics, 2021-2031 (USD Mn, AGR (%)
Figure 228. Asia-Pacific Direct To Patient Market Logistics, 2021-2031 (USD Mn, AGR (%) (V – Shaped Recovery)
Figure 229. Asia-Pacific Direct To Patient Market Logistics, 2021-2031 (USD Mn, AGR (%) (W – Shaped Recovery)
Figure 230. Asia-Pacific Direct To Patient Market Logistics, 2021-2031 (USD Mn, AGR (%) (U – Shaped Recovery)
Figure 231. Asia-Pacific Direct To Patient Market Logistics, 2021-2031 (USD Mn, AGR (%) (L – Shaped Recovery)
Figure 232. Asia-Pacific Direct To Patient Market by Therapeutics, 2021-2031 (USD Mn, AGR (%)
Figure 233. Asia-Pacific Direct To Patient Market by Therapeutics, 2021-2031 (USD Mn, AGR (%) (V – Shaped Recovery)
Figure 234. Asia-Pacific Direct To Patient Market by Therapeutics, 2021-2031 (USD Mn, AGR (%) (W – Shaped Recovery)
Figure 235. Asia-Pacific Direct To Patient Market by Therapeutics, 2021-2031 (USD Mn, AGR (%) (U – Shaped Recovery)
Figure 236. Asia-Pacific Direct To Patient Market by Therapeutics, 2021-2031 (USD Mn, AGR (%) (L – Shaped Recovery)
Figure 237. Asia-Pacific Direct To Patient Market by Model, 2021-2031 (USD Mn, AGR (%)
Figure 238. Asia-Pacific Direct To Patient Market by Model, 2021-2031 (USD Mn, AGR (%) (V-Shaped Recovery)
Figure 239. Asia-Pacific Direct To Patient Market by Model, 2021-2031 (USD Mn, AGR (%) (W-Shaped Recovery)
Figure 240. Asia-Pacific Direct To Patient Market by Model, 2021-2031 (USD Mn, AGR (%) (U-Shaped Recovery)
Figure 241. Asia-Pacific Direct To Patient Market by Model, 2021-2031 (USD Mn, AGR (%) (L-Shaped Recovery)
Figure 242. China Asia-Pacific Direct-to-Patient Market by Value, 2021-2031 (USD Mn, AGR (%)
Figure 243. China Direct-to-Patient Market by Value, 2021-2031 (USD Mn, AGR (%) (V – Shaped Recovery)
Figure 244. China Direct-to-Patient Market by Value, 2021-2031 (USD Mn, AGR (%) (W – Shaped Recovery)
Figure 245. China Direct-to-Patient Market by Value, 2021-2031 (USD Mn, AGR (%) (U – Shaped Recovery)
Figure 246. China Direct-to-Patient Market by Value, 2021-2031 (USD Mn, AGR (%) (L – Shaped Recovery)
Figure 247. India Asia-Pacific Direct-to-Patient Market by Value, 2021-2031 (USD Mn, AGR (%)
Figure 248. India Direct-to-Patient Market by Value, 2021-2031 (USD Mn, AGR (%) (V – Shaped Recovery)
Figure 249. India Direct-to-Patient Market by Value, 2021-2031 (USD Mn, AGR (%) (W – Shaped Recovery)
Figure 250. India Direct-to-Patient Market by Value, 2021-2031 (USD Mn, AGR (%) (U – Shaped Recovery)
Figure 251. India Direct-to-Patient Market by Value, 2021-2031 (USD Mn, AGR (%) (L – Shaped Recovery)
Figure 252. Japan Direct-to-Patient Market by Value, 2021-2031 (USD Mn, AGR (%)
Figure 253. Japan Direct-to-Patient Market by Value, 2021-2031 (USD Mn, AGR (%) (V – Shaped Recovery)
Figure 254. Japan Direct-to-Patient Market by Value, 2021-2031 (USD Mn, AGR (%) (W – Shaped Recovery)
Figure 255. Japan Direct-to-Patient Market by Value, 2021-2031 (USD Mn, AGR (%) (U – Shaped Recovery)
Figure 256. Japan Direct-to-Patient Market by Value, 2021-2031 (USD Mn, AGR (%) (L – Shaped Recovery)
Figure 257. South Korea Direct-to-Patient Market by Value, 2021-2031 (USD Mn, AGR (%)
Figure 258. South Korea Direct-to-Patient Market by Value, 2021-2031 (USD Mn, AGR (%) CAGR (%)) (V – Shaped Recovery)
Figure 259. South Korea Direct-to-Patient Market by Value, 2021-2031 (USD Mn, AGR (%) (W – Shaped Recovery)
Figure 260. South Korea Direct-to-Patient Market by Value, 2021-2031 (USD Mn, AGR (%) (U – Shaped Recovery)
Figure 261. South Korea Direct-to-Patient Market by Value, 2021-2031 (USD Mn, AGR (%) (L – Shaped Recovery)
Figure 262. Australia Direct-to-Patient Market by Value, 2021-2031 (USD Mn, AGR (%)
Figure 263. Australia Direct-to-Patient Market by Value, 2021-2031 (USD Mn, AGR (%) (V – Shaped Recovery)
Figure 264. Australia Direct-to-Patient Market by Value, 2021-2031 (USD Mn, AGR (%) (W – Shaped Recovery)
Figure 265. Australia Direct-to-Patient Market by Value, 2021-2031 (USD Mn, AGR (%) (U – Shaped Recovery)
Figure 266. Australia Direct-to-Patient Market by Value, 2021-2031 (USD Mn, AGR (%) (L – Shaped Recovery)
Figure 267. Rest of Asia-Pacific Direct-to-Patient Market by Value, 2021-2031 (USD Mn, AGR (%)
Figure 268. Rest of Asia-Pacific Direct-to-Patient Market by Value, 2021-2031 (USD Mn, AGR (%) (V – Shaped Recovery)
Figure 269. Rest of Asia-Pacific Direct-to-Patient Market by Value, 2021-2031 (USD Mn, AGR (%) (W – Shaped Recovery)
Figure 270. Rest of Asia-Pacific Direct-to-Patient Market by Value, 2021-2031 (USD Mn, AGR (%) (U – Shaped Recovery)
Figure 271. Rest of Asia-Pacific Direct-to-Patient Market by Value, 2021-2031 (USD Mn, AGR (%) (L – Shaped Recovery)
Figure 272. LAMEA Direct To Patient Market by Value, 2021-2031 (USD Mn, AGR (%)
Figure 273. LAMEA Direct-to-Patient Market by Value, 2021-2031 (USD Mn, AGR (%) (V – Shaped Recovery)
Figure 274. LAMEA Direct To Patient Market by Value, 2021-2031 (USD Mn, AGR (%) (W – Shaped Recovery)
Figure 275. LAMEA Direct To Patient Market by Value 2021-2031 (USD Mn, AGR (%) (U – Shaped Recovery)
Figure 276. LAMEA Direct To Patient Market by Value, 2021-2031 (USD Mn, AGR (%) (L – Shaped Recovery)
Figure 277. LAMEA Direct To Patient Market by Country, 2021-2031 (USD Mn, AGR (%)
Figure 278. LAMEA Direct To Patient Market by Country, 2021-2031 (USD Mn, AGR (%) (V – Shaped Recovery)
Figure 279. LAMEA Direct To Patient Market by Country, 2021-2031 (USD Mn, AGR (%) (W – Shaped Recovery)
Figure 280. LAMEA Direct To Patient Market by Country, 2021-2031 (USD Mn, AGR (%) (U – Shaped Recovery)
Figure 281. LAMEA Direct To Patient Market by Country, 2021-2031 (USD Mn, AGR (%) (L – Shaped Recovery)
Figure 282. LAMEA Direct To Patient Market by Type, 2021-2031 (USD Mn, AGR (%)
Figure 283. LAMEA Direct To Patient Market by Type, 2021-2031 (USD Mn, AGR (%) (V-Shaped Recovery)
Figure 284. LAMEA Direct To Patient Market by Type, 2021-2031 (USD Mn, AGR (%) (W-Shaped Recovery)
Figure 285. LAMEA Direct To Patient Market by Type, 2021-2031 (USD Mn, AGR (%) (U-Shaped Recovery)
Figure 286. LAMEA Direct To Patient Market by Type, 2021-2031 (USD Mn, AGR (%) (L-Shaped Recovery)
Figure 287. LAMEA Direct To Patient Market by Marketing , 2021-2031 (USD Mn, AGR (%)
Figure 288. LAMEA Direct To Patient Market by Marketing , 2021-2031 (USD Mn, AGR (%) (V – Shaped Recovery)
Figure 289. LAMEA Direct To Patient Market by Marketing , 2021-2031 (USD Mn, AGR (%) (W – Shaped Recovery)
Figure 290. LAMEA Direct To Patient Market by Marketing , 2021-2031 (USD Mn, AGR (%) (U – Shaped Recovery)
Figure 291. LAMEA Direct To Patient Market by Marketing , 2021-2031 (USD Mn, AGR (%) (L – Shaped Recovery)
Figure 292. LAMEA Direct To Patient Market by Health Services, 2021-2031 (USD Mn, AGR (%)
Figure 293. LAMEA Direct To Patient Market by Health Services, 2021-2031 (USD Mn, AGR (%) (V – Shaped Recovery)
Figure 294. LAMEA Direct To Patient Market by Health Services, 2021-2031 (USD Mn, AGR (%) (W – Shaped Recovery)
Figure 295. LAMEA Direct To Patient Market by Health Services, 2021-2031 (USD Mn, AGR (%) (U – Shaped Recovery)
Figure 296. LAMEA Direct To Patient Market by Health Services, 2021-2031 (USD Mn, AGR (%) (L – Shaped Recovery)
Figure 297. LAMEA Direct To Patient Market by Clinical Trials , 2021-2031 (USD Mn, AGR (%)
Figure 298. LAMEA Direct To Patient Market by Clinical Trials , 2021-2031 (USD Mn, AGR (%) (V – Shaped Recovery)
Figure 299. LAMEA Direct To Patient Market by Clinical Trials , 2021-2031 (USD Mn, AGR (%) (W – Shaped Recovery)
Figure 300. LAMEA Direct To Patient Market by Clinical Trials , 2021-2031 (USD Mn, AGR (%) (U – Shaped Recovery)
Figure 301. LAMEA Direct To Patient Market by Clinical Trials , 2021-2031 (USD Mn, AGR (%) (L – Shaped Recovery)
Figure 302. LAMEA Direct To Patient Market Logistics, 2021-2031 (USD Mn, AGR (%)
Figure 303. LAMEA Direct To Patient Market Logistics, 2021-2031 (USD Mn, AGR (%) (V – Shaped Recovery)
Figure 304. LAMEA Direct To Patient Market Logistics, 2021-2031 (USD Mn, AGR (%) (W – Shaped Recovery)
Figure 305. LAMEA Direct To Patient Market Logistics, 2021-2031 (USD Mn, AGR (%) (U – Shaped Recovery)
Figure 306. LAMEA Direct To Patient Market Logistics, 2021-2031 (USD Mn, AGR (%) (L – Shaped Recovery)
Figure 307. LAMEA Direct To Patient Market by Therapeutics, 2021-2031 (USD Mn, AGR (%)
Figure 308. LAMEA Direct To Patient Market by Therapeutics, 2021-2031 (USD Mn, AGR (%) (V – Shaped Recovery)
Figure 309. LAMEA Direct To Patient Market by Therapeutics, 2021-2031 (USD Mn, AGR (%) (W – Shaped Recovery)
Figure 310. LAMEA Direct To Patient Market by Therapeutics, 2021-2031 (USD Mn, AGR (%) (U – Shaped Recovery)
Figure 311. LAMEA Direct To Patient Market by Therapeutics, 2021-2031 (USD Mn, AGR (%) (L – Shaped Recovery)
Figure 312. LAMEA Direct To Patient Market by Model, 2021-2031 (USD Mn, AGR (%)
Figure 313. LAMEA Direct To Patient Market by Model, 2021-2031 (USD Mn, AGR (%) (V-Shaped Recovery)
Figure 314. LAMEA Direct To Patient Market by Model, 2021-2031 (USD Mn, AGR (%) (W-Shaped Recovery)
Figure 315. LAMEA Direct To Patient Market by Model, 2021-2031 (USD Mn, AGR (%) (U-Shaped Recovery)
Figure 316. LAMEA Direct To Patient Market by Model, 2021-2031 (USD Mn, AGR (%) (L-Shaped Recovery)
Figure 317. LAMEA Direct-to-Patient Market by Value, 2021-2031 (USD Mn, AGR (%)
Figure 318. Brazil Direct-to-Patient Market by Value, 2021-2031 (USD Mn, AGR (%) (V – Shaped Recovery)
Figure 319. Brazil Direct-to-Patient Market by Value, 2021-2031 (USD Mn, AGR (%) (W – Shaped Recovery)
Figure 320. Brazil Direct-to-Patient Market by Value, 2021-2031 (USD Mn, AGR (%) (U – Shaped Recovery)
Figure 321. Brazil Direct-to-Patient Market by Value, 2021-2031 (USD Mn, AGR (%) (L – Shaped Recovery)
Figure 322. South Africa Direct-to-Patient Market by Value, 2021-2031 (USD Mn, AGR (%)
Figure 323. South Africa Direct-to-Patient Market by Value, 2021-2031 (USD Mn, AGR (%) (V – Shaped Recovery)
Figure 324. South Africa Direct-to-Patient Market by Value, 2021-2031 (USD Mn, AGR (%) (W – Shaped Recovery)
Figure 325. South Africa Direct-to-Patient Market by Value, 2021-2031 (USD Mn, AGR (%) (U – Shaped Recovery)
Figure 326. South Africa Direct-to-Patient Market by Value, 2021-2031 (USD Mn, AGR (%) (L – Shaped Recovery)
Figure 327. Saudi Arabia Direct-to-Patient Market by Value, 2021-2031 (USD Mn, AGR (%)
Figure 328. Saudi Arabia Direct-to-Patient Market by Value, 2021-2031 (USD Mn, AGR (%) (V – Shaped Recovery)
Figure 329. Saudi Arabia Direct-to-Patient Market by Value, 2021-2031 (USD Mn, AGR (%) (W – Shaped Recovery)
Figure 330. Saudi Arabia Direct-to-Patient Market by Value, 2021-2031 (USD Mn, AGR (%) (U – Shaped Recovery)
Figure 331. Saudi Arabia Direct-to-Patient Market by Value, 2021-2031 (USD Mn, AGR (%) (L – Shaped Recovery)
Figure 332. Turkey Direct-to-Patient Market by Value, 2021-2031 (USD Mn, AGR (%)
Figure 333. Turkey Direct-to-Patient Market by Value, 2021-2031 (USD Mn, AGR (%) (V – Shaped Recovery)
Figure 334. Turkey Direct-to-Patient Market by Value, 2021-2031 (USD Mn, AGR (%) (W – Shaped Recovery)
Figure 335. Turkey Direct-to-Patient Market by Value, 2021-2031 (USD Mn, AGR (%) (U – Shaped Recovery)
Figure 336. Turkey Direct-to-Patient Market by Value, 2021-2031 (USD Mn, AGR (%) CAGR (%)) (L – Shaped Recovery)
Figure 337. UAE Direct-to-Patient Market by Value, 2021-2031 (USD Mn, AGR (%)
Figure 338. UAE Direct-to-Patient Market by Value, 2021-2031 (USD Mn, AGR (%) (V – Shaped Recovery)
Figure 339. UAE Direct-to-Patient Market by Value, 2021-2031 (USD Mn, AGR (%) (W – Shaped Recovery)
Figure 340. UAE Direct-to-Patient Market by Value, 2021-2031 (USD Mn, AGR (%) (U – Shaped Recovery)
Figure 341. UAE Direct-to-Patient Market by Value, 2021-2031 (USD Mn, AGR (%) (L – Shaped Recovery)
Figure 342. Rest of LAMEA Direct-to-Patient Market by Value, 2021-2031 (USD Mn, AGR (%)
Figure 343. Rest of LAMEA Direct-to-Patient Market by Value, 2021-2031 (USD Mn, AGR (%) (V – Shaped Recovery)
Figure 344. Rest of LAMEA Direct-to-Patient Market by Value, 2021-2031 (USD Mn, AGR (%) (W – Shaped Recovery)
Figure 345. Rest of LAMEA Direct-to-Patient Market by Value, 2021-2031 (USD Mn, AGR (%) (U – Shaped Recovery)
Figure 346. Rest of LAMEA Direct-to-Patient Market by Value, 2021-2031 (USD Mn, AGR (%) (L – Shaped Recovery)
Figure 347. Direct-to-Patient Market by Company Share, 2020 (%)
Figure 348. Direct-to-Patient Market by Key Business Strategy, 2018-2021 (%)
Figure 349. American Well : Company Revenue 2018-2020 (US$Mn, AGR %)
Figure 350. American Well : Company Operating Income 2018-2020 (US$Mn, AGR %)
Figure 351. American Well : Company Net Income 2018-2020 (US$Mn, AGR %)
Figure 352. American Well : Company EBITDA 2018-2020 (US$Mn, AGR %)
Figure 353. Teladoc, Inc. : Company Revenue 2016-2020 (US$Mn, AGR %)
Figure 354. Teladoc, Inc. : Company Operating Income 2016-2020 (US$Mn, AGR %)
Figure 355. Teladoc, Inc. : Company Net Income 2016-2020 (US$Mn, AGR %)
Figure 356. Teladoc, Inc. : Company EBITDA 2016-2020 (US$Mn, AGR %)
List of Companies Profiled in the report
20/20NOW
Access Physicians
AGNITY Global Inc.
AMD Global Telemedicine, Inc.
American Well Corporation
Avera eCARE
Axs Healthcare
Babylon Health
CitiusTech Inc.
Dictum Health
Doctor Anywhere Pte. Ltd.
Doctor on Demand
Health Tap
HealthPartners, Inc.
Hims & Hers Health, Inc.
Marken
Nurx
Practo Technologies Private Limited
Specialists On Call Inc.
Teladoc Health, Inc.
TRUEPILL, LTD
UpScript Health
List of Other Companies Mentioned in the report
All scripts Healthcare Solutions, Inc.
Antidote
Athenahealth, Inc.
AutoCruitment
BBK Worldwide
Cerner Corporation
Clariness
ClinicalConnection
CSSi
Curavit
Elligo Health Research
Getwell Network, Inc.
IBM
Langland
Lincor Solutions
McKesson Corporation
Medecision, Inc.
MMG
Orion Health Ltd.
Phytel Inc.
Praxis
Science37
StudyKik
TrialSpark
TrialX
Welvu
Yourcareuniverse, Inc.
List of Associations Mentioned in the Report
Africa Centres for Disease Control and Prevention (Africa CDC)
American Association of Medical Colleges (AAMC)
Astar's Genome institute of Singapore (GIS)
Biocertis group
Biotechnology Industry Research Assistance council (BIRAC)
Clinical Laboratory Improvement Amendments (CLIA)
Clinical Laboratory Improvement Amendments (CLIA)
Diagnostic Related Group (DRG)
Food and Drug Administration (FDA)
Indian Department of Biotechnology (DBT)
Indian institute of technology (IIT)
Indian Medical Device Industry (AIMED)
International Diabetes Federation (IDF)
International Organisation for Standardisation (ISO)
Nichirel Bioscience
The Foundation for Innovative New Diagnostics (FIND)
World health Organization (WHO)
Visiongain Pharma
Visiongain Pharma
Visiongain Pharma
